





# Empowering Knowledge

Алексей Моисеев, MBA  
Руководитель направления LifeScience  
Elsevier S&T в России, Турции и странах СНГ

26/02/2020

# Журналы Elsevier



- Более **20 скачиваний в секунду**
- Более **15 млн пользователей** по всему миру
- **>23%** всех опубликованных в мире научных статей\*
- **21% среди 1% наиболее цитируемых статей**
- **61 журнал Elsevier занимает первое место** в своей научной категории по импакт-фактору
- В 2014 году **103 новых журнала**

\*по данным Scopus

# Решения в области life sciences


НАПРАВЛЕННЫ НА КЛЮЧЕВЫЕ ПРОБЛЕМЫ В R&D



Продукты Elsevier охватывают всю цепочку "От геномов к лекарству in silico"

## Что такое анализ сигнальных путей?

- Анализ сигнальных путей – это изучение взаимодействий между клеточными компонентами (ДНК, РНК, белки), и другими соединениями, которые могут взаимодействовать с ними (например, малые молекулы, химические вещества, метаболиты).
- Эти взаимодействия описывают биологические процессы.



# MedScan извлекает факты из документов. Это не просто индексированный поиск

“It is well established that phosphorylation of **β-catenin** by **GSK3β** enhances binding of **β-catenin** to **Axin** and **Adenomatous Polyposis Coli** in hepatocytes.”





NLP: семантические триплеты

<b>Axin</b>	<u>binding of</u>	<b>β-catenin</b>
<b>Axin</b>	<u>binding of</u>	<b>Adenomatous Polyposis Coli</b>
<b>β-catenin</b>	<u>phosphorylation by</u>	<b>GSK3β</b>




Извлеченные взаимосвязи

**Axin1 – CTNNB1**, связь: Binding  
**Axin1 – APC**, связь : Binding  
**GSK-3B->Axin** связь : ProtModification, Cell Type:






## На какие почечные процессы повлияет прием sorafenib, sunitinib, everolimus, pazopanib, axitinib ?






# Предсказание в Pathway Studio: Обнаружение биомаркеров эффективности в Pathway Studio



# Предсказание в Pathway Studio: Репозиционирование лекарств



# Pathway Studio

Pathway Studio – мощное исследовательское решение, которое помогает ученым

- **Визуализировать литературу**, создавать и применять молекулярные **модели сигнальных путей**,
- **интерпретировать** крупно масштабные молекулярные **данные профилирование**
  
- На основе комплексной и богатой знаниями база данных **миллионов биологических фактов** с использованием литературы и сотен курируемых сигнальных путей.
  
- Изучать заболевание
- Выбирать мишени
- Перепрофилировать препараты


# Решения в области life sciences

НАПРАВЛЕННЫ НА КЛЮЧЕВЫЕ ПРОБЛЕМЫ В R&D



Продукты Elsevier охватывают всю цепочку "От геномов к лекарству in silico"

Информационная система, построенная для отражения реального использования химических знаний



>105 Млн Записей соединений с  
 >500 Млн извлеченных фактов  
 об их свойствах: физические,  
 химические, спектральные,  
 экологические, биоактивность



>41 Млн Записей реакций  
 включают извлеченные  
 данные об условиях  
 проведения реакций,  
 растворителях,  
 катализаторах, выходе

**Основные принципы химии**



51.9 Млн записей Литературы  
 из 16,000 периодических изданий  
 описывая применения в области  
 материало-ведения,  
 биомедицины, наук о Земле,  
 технических и экологических наук,  
 фармакологии...

**Применение в  
 различных  
 дисциплинах**

# Reaxys источники для научного контента

**16.000 titles**

(journals, books and patents)

**56+mio articles**

(Elsevier, ACS, Nature-Springer, Blackwell, Taylor and Francis, etc)

**1,5+mio patents**

WPO, USPO, EPO [≈ mid 70's >]


PO: JP, KR, CN, TW [2015 >]

**380+k book chapters**

Beilstein, Gmelin, ....



**≈ 450 journals + PO**  
**[manually excerpted]**



Из экспериментальных данных статей из рецензируемых журналов и патентов

3784 *J. Med. Chem.* 2009, 52, 3784–3793

**High-Affinity, Non-Nucleotide-Derived Competitive Antagonists of Platelet P2Y<sub>12</sub> Receptors**

Younis Baqi,<sup>1</sup> Kerstin Atzler,<sup>1</sup> Meryem Köse,<sup>1</sup> Markus Glänzel,<sup>1,4</sup> and Christa E. Müller<sup>1\*</sup>

*PharmaCenter Bonn, Pharmaceutical Institute, Pharmaceutical Chemistry I, Pharmaceutical Sciences Bonn (PSB), University of Bonn, An der Sternburg 4, D-53121 Bonn, Germany; Department of Experimental and Clinical Pharmacology and Toxicology, University of Freiburg, Albertstraße 25, D-79104 Freiburg, Germany*

Received March 16, 2009

Anthraquinone derivatives related to the moderately potent, nonselective P2Y<sub>12</sub> receptor antagonist reactive blue 2 (6) have been synthesized and optimized with respect to P2Y<sub>12</sub> receptor affinity. A radioligand binding assay utilizing human blood platelet membranes and the P2Y<sub>12</sub> receptor-selective antagonist radioligand [<sup>3</sup>H]-propylthioadenosine-5'-adenylic acid (1-[1-dichloro-1-phosphonomethyl-1-phosphonyl] anhydride [<sup>3</sup>H]PSB-0413) was applied for compound testing. 1-Amino-2-sulfanthraquinone derivatives bearing a *o*-phenylamino/anilino substitution in the 4-position and an additional acidic function in the *meta*-position of the aniline ring showed high P2Y<sub>12</sub> receptor affinity. These new anthraquinone derivatives became accessible by a recently developed copper(0)-catalyzed Ullmann coupling reaction of 1-amino-4-bromoanthraquinone derivatives with anilines in aqueous buffer under microwave irradiation. The most potent compounds



**Reaxus извлекает все необходимые данные даже из примечаний и текста**

appears to be of paramount importance in regulating platelet function and, as a consequence, in controlling thrombotic diseases, which are the most common cause of morbidity and mortality in industrialized countries. (i) moderate potency (therefore high doses are required), and (v) difficulties in steering and controlling the effects.




Therefore, it is highly desirable to develop P2Y<sub>12</sub> antagonists that are lacking the drawbacks associated with the standard P2Y<sub>12</sub> antagonists such as clopidogrel and other thienopyridine derivatives. Several groups have recently been developing competitive, reversible P2Y<sub>12</sub> antagonists that may be superior to clopidogrel and related drugs. Most approaches started from the adenine nucleotides as lead structures, ADP,

\* To whom correspondence should be addressed. Phone: +49-228-73-2301. Fax: +49-228-73-2567. E-mail: christa.mueller@uni-bonn.de.  
<sup>1</sup> PharmaCenter Bonn, Pharmaceutical Institute, Pharmaceutical Chemistry I, Pharmaceutical Sciences Bonn (PSB), University of Bonn, Department of Experimental and Clinical Pharmacology and Toxicology, University of Freiburg.  
<sup>2</sup> Present address: Elsevier Pharma Biotech Group, Elsevier Information Systems GmbH, Theodor-Heuss-Allee 108, D-60486 Frankfurt (Main), Germany.

10.1021/jm9003297 CCC: \$40.75 © 2009 American Chemical Society  
 Published on Web 05/22/2009



- Физические свойства
- Спектры
- Биоактивность
- Природные материалы



Свойства химических соединений и их взаимодействия являются ключевыми для способа организации данных в базе данных. Также индексируется информация о физико-химических и фармакологических свойствах.

Это обширные, хорошо проиндексированные данные под рукой

Reaxys является крупнейшим хранилищем данных о свойствах веществ в мире.  
Растворимость это только одно из **>500 полей данных для поиска** в Reaxys

Melting point

Boiling point

Sublimation

Refractive index

Density

Adsorption

Association

Autoignition

Bound Surface Phenomena

Viscosity

Circular Dichromism

Complex Phase Equilibria

Compressibility

Conformation

Critical Density

Critical Micelle Concentration

Critical Pressure

Critical Temperature

Critical Volume

Electrical Data

Electrical Moment

Electrochemistry Data

Electron Binding

Energy Barriers

Energy Data

Enthalpy of Formation

Enthalpy of Sublimation

Flash Point

Gas Phase

Dissociation Energy

Crystal System

Crystal Phase

Heat Capacity

Henry Constat

Ionization Potential

Isoelectric Point

Kinematic Viscosity

Liquid Phase

Magnetic Data

Mechanical Properties

Molecular Deformation

Optical Data

Thermochemical Data

Solubility

Solution Behavior

Sound Properties

Static Dielectric Constat

Surface Tension

Transition Points

Transport Data

**Solubility**

NMR Spectroscopy

IR Spectroscopy

Mass Spectroscopy

UV/VIS Spectroscopy

ESR Spectroscopy

NQR Spectroscopy

Raman Spectroscopy

Luminescence Spectroscopy

Fluorescence Spectroscopy

Exposure Assessment

Bioaccumulation

Biomagnification

Biodegradation

Biodegradation

Stability in Soil

Oxygen Demand

Uses

Isolation from Natural Prod.

Reaction Yield

Reaction Conditions

Reaction Type

Named Reaction

Pharmacological Data

Route of Administration

Concentration

Target

Substance Effect

Substance Action on Target

Substance Dose

Bioassay

Animal Model

Organs/Tissue

Cells/Cell Lines

Measurement Parameter

Endpoint of Effect

Ecotoxicology Data

Dielectric Constant

Dissociation Exponent

Dynamic Viscosity

Electrolytic Conductivity

Enthalpy of Fusion

Enthalpy of Vaporization

Explosion Limits

Interatomic Distance/Angle

Kinematic Viscosity


Liquid/Solid Systems

Liquid/Vapor Systems

Metarotation

And many more...

# Вы получаете данные непосредственно извлеченные данные



Physical Data - 766

✓ Melting Point - 43

✓ Sublimation - 2

✓ Refractive Index - 2

✓ Density - 9

✓ Adsorption (MCS) - 23

✓ Association (MCS) - 22

✓ Boundary Surface Phenomena - 1

✓ Chromatographic Data - 1

✓ Conformation - 1

✓ Crystal Phase - 7

✓ Crystal Property Description - 1

✓ Crystal System - 2

✓ Decomposition - 1

✓ Heat Capacity Cp - 2


✓ Heat Capacity Cp0 - 1

✓ **Solubility (MCS) - 102**

✓ Solution Behaviour (MCS) - 20

Solubility, g·l <sup>-1</sup>	Saturation	Temperature (Solubility (MCS))	Solvent (Solubility (MCS))	Comment (Solubility (MCS))	Reference
20.88		28	water		<a href="#">Singh, Neetu; Singh, Udai P.; Nikhil, Kumar; Roy, Partha; Singh, Hariji</a> Full Text ↗ Details > Abstract >
	in pure solvent	25	methanol	Solubility: 1.23 g/100g solvent	<a href="#">Guo, Kun; Sadiq, Ghazala; Seaton, Colin; Davey, Roger; Yin, Qiuxiang</a> Full Text ↗ Cited 42 times ↗ Details > Abstract >
	in pure solvent	25	ethanol	Solubility: 1.48 g/100g solvent	<a href="#">Guo, Kun; Sadiq, Ghazala; Seaton, Colin; Davey, Roger; Yin, Qiuxiang</a> Full Text ↗ Cited 42 times ↗ Details > Abstract >
	in pure solvent	25	acetone	Solubility: 1.51 g/100g solvent	<a href="#">Guo, Kun; Sadiq, Ghazala; Seaton, Colin; Davey, Roger; Yin, Qiuxiang</a> Full Text ↗ Cited 42 times ↗ Details > Abstract >

# Tofacitinib



## Tofacitinib citrate

$C_6H_8O_7 \cdot C_{16}H_{20}N_6O$  504.5 11610699

Identification

Druglikeness

Bioactivity (All)

Physical Data - 27

Spectra - 15

Other Data - 47

Preparations - 51 >

Reactions - 55 >

Targets - 28 >

Documents - 52 >



Quantitative Results

Show/Hide columns 

pX	Parameter	Value (qual)	Value (quant)	Unit	Biological Species	Action on target	Target	Tissue/Organ	Cell	Bioassay	Dose	Concomitants	Reference
9	IC50		1	nM			Tyrosine-protein kinase JAK3 [human]:Wild		Sf9 cell line	Enzymology inhibition		CoEnzyme: ATP	<a href="#">Flanagan, Mark E.; Blumenkopf, Todd A.; Brissette, William H.; Brown, Matthew F.; Casavant, Jeffrey M.; Shang-Poa, Chang; Doty, Jonathan I (...)</a> <a href="#">Whipple, David A.; Changelian, Paul S.</a> <b>Journal of Medicinal Chemistry</b> , 2010, vol. 53, # 24, p. 8468 - 8484] <a href="#">Full Text</a>  <a href="#">Cited 206 times</a>  <a href="#">Details</a>  <a href="#">Abstrac</a>
7.28	inhibition rate (Phosphorylation rate)		99	%		Inhibitor	Tyrosine-protein kinase JAK1 [human]:Wild				1 µM		Yang Ji Chemical Co., Ltd.; Han W'ha Pharma Co., Ltd.; KI Jong Hoon; CHOUGH, Chi Yeon; JEONG, Hyun Uk; LEE, Sun Min; JOUNG, Mi Suk; (...) MOON, Hong Sik; KIM, Kyoung Rak - EP3196199, 2017, A2 <a href="#">Full Text</a>  <a href="#">Details</a>  <a href="#">Abstract</a> 
7.28	inhibition rate (Phosphorylation rate)		98	%		Inhibitor	Tyrosine-protein kinase JAK2 [human]:Wild				1 µM		Yang Ji Chemical Co., Ltd.; Han W'ha Pharma Co., Ltd.; KI Jong Hoon; CHOUGH, Chi Yeon; JEONG, Hyun Uk; LEE, Sun Min; JOUNG, Mi Suk; (...) MOON, Hong Sik; KIM, Kyoung Rak - EP3196199, 2017, A2 <a href="#">Full Text</a>  <a href="#">Details</a>  <a href="#">Abstract</a> 
7.28	inhibition rate (Phosphorylation rate)		99	%		Inhibitor	Tyrosine-protein kinase JAK3 [human]:Wild				1 µM		Yang Ji Chemical Co., Ltd.; Han W'ha Pharma Co., Ltd.; KI Jong Hoon; CHOUGH, Chi Yeon; JEONG, Hyun Uk; LEE, Sun Min; JOUNG, Mi Suk; (...) MOON, Hong Sik; KIM, Kyoung Rak - EP3196199, 2017, A2 <a href="#">Full Text</a>  <a href="#">Details</a>  <a href="#">Abstract</a> 
7.28	inhibition rate		100	%		Inhibitor	Non-receptor				1 µM		Yang Ji Chemical Co., Ltd.; Han W'ha Pharma Co., Ltd.; KI

^ [In vivo: Animal Model - 10](#)

**Quantitative Results**

Show/Hide columns 

Parameter	Value (qual)	Value (quant)	Unit	Biological Species	Animal Model	Route of administration	Dose	Effect	Reference
LD50		1000	mg/kg	mouse		intragastric administration		Toxic : Acute	MEDIVATION NEUROLOGY, INC. - WO2008/69963, 2008, A1 <a href="#">Full Text</a> <a href="#">Details</a> <a href="#">Abstract</a>
Activity (OC50)	=	355	nM	rat		intraperitoneal administration			Schaffhauser, Herve; Mathiasen, Joanne R; Dicamillo, Amy; Huffman, Mark J; Lu, Lily D; McKenna, Beth A; Qian, Jie; Marino, Michael J[Biochemical Pharmacology, 2009, vol. 78, # 8, p. 1035 - 1042] <a href="#">Full Text</a> <a href="#">Details</a> <a href="#">Abstract</a>
time of spent in plarform increase	Active			Bagg albino mouse	scopolamine-induced cognitive defect	intraintestinal administration	0.1 mg/kg	nootropic agent	Ivachtchenko, Alexandre Vasilievich; Ivashchenko, Andrey Alexandrovich; Savchuk, Nikolay Filippovich - US2019/233409, 2019, A1 <a href="#">Full Text</a> <a href="#">Details</a> <a href="#">Abstract</a>

**Qualitative Results**

1 of 7	Biological material	mouse
	Assay Description	Effect : retinal degeneration; effect on Species : mouse expressing mutant form of ELO VL4 [0126] In vivo models of ocular diseases can be used to determine the ability of any of the hydrogenated pyrido[4,3-b]indoles described herein (e.g., dimebon) or combination therapies to treat and/or prevent and/or delay the onset and/or the development of a neuronal death mediated ocular disease.[0127]
	Reference	MEDIVATION NEUROLOGY, INC. - WO2009/39420, 2009, A1 <a href="#">Full Text</a> <a href="#">Details</a> <a href="#">Abstract</a>
2 of 7	Assay Description	Effect : Acute Experimental Allergic Encephalomyelitis (EAE); effect onAcute Experimental Allergic Encephalomyelitis (EAE); effect onAcute Experimental Allergic Encephalomyelitis (EAE); effect on Bioassay : C57BL/6J mouse with Experimental Allergic Encephalomyelitis (EAE) induced by MOG peptide EXAMPLE. Acute EAE Murine Model. Experimental AllergicEncephalomyelitis (EAE) is a central nervous system (CNS) autoimmune demyelinating disease that mimics many of the clinical and pathologic features of Multiple Sclerosis (MS). The MOG murine model consists of a sensitization period, induced
	Results	Clinical score after 35 days of daily treatment = ca 5 at 1.0 mg/kg; ca 9 at 10.0 mg/kg; ca 4 for positive control; ca 10 for vehicle control
	Reference	BIOVISTA, INC.; DEFTEREOS, Spyros; PERSIDIS, Andreas - WO2010/45265, 2010, A1 <a href="#">Full Text</a> <a href="#">Details</a> <a href="#">Abstract</a>

Metabolism - 152

Quantitative Results

Show/Hide columns 

pX	Parameter	Value (qual)	Value (quant)	Unit	Action on target	Target	Cell	Substrate / Carried Molecule	Dose	Concomitants	Reference
5.2	Fold-increase	Active							6.25000 $\mu\text{M}$		No author[Type: Clinical Pharmacology Biopharmaceutics Review, Lab: NDA203214, Owner: PFIZER INC, Number: 000, 2012] <a href="#">Full Text</a>  <a href="#">Details</a>  <a href="#">Abstract</a> 
4.41	inhibition rate		44.4	%	Inhibitor	<a href="#">Solute carrier organic anion transporter family member 1B1 [human]:Wild</a>	HEK293 cell line	Pravastatin	31.2500 $\mu\text{M}$	Substrate: Pravastatin	No author[Type: Clinical Pharmacology Biopharmaceutics Review, Lab: NDA203214, Owner: PFIZER INC, Number: 000, 2012] <a href="#">Full Text</a>  <a href="#">Details</a>  <a href="#">Abstract</a> 
4.37	inhibition rate		59.2	%	Inhibitor	<a href="#">Solute carrier organic anion transporter family member 1B1 [human]:Wild</a>	HEK293 cell line	Pravastatin	62.5000 $\mu\text{M}$	Substrate: Pravastatin	No author[Type: Clinical Pharmacology Biopharmaceutics Review, Lab: NDA203214, Owner: PFIZER INC, Number: 000, 2012] <a href="#">Full Text</a>  <a href="#">Details</a>  <a href="#">Abstract</a> 
4.26	IC50		55.3	$\mu\text{M}$	Inhibitor	<a href="#">Solute carrier organic anion transporter family member 1B1 [human]:Wild</a>	HEK293 cell line	Pravastatin	0.0100000 $\mu\text{M}$	Substrate: Pravastatin	No author[Type: Clinical Pharmacology Biopharmaceutics Review, Lab: NDA203214, Owner: PFIZER INC, Number: 000, 2012] <a href="#">Full Text</a>  <a href="#">Details</a>  <a href="#">Abstract</a> 
4.23	inhibition rate		68.2	%	Inhibitor	<a href="#">Solute carrier organic anion transporter family member 1B1 [human]:Wild</a>	HEK293 cell line	Pravastatin	125 $\mu\text{M}$	Substrate: Pravastatin	No author[Type: Clinical Pharmacology Biopharmaceutics Review, Lab: NDA203214, Owner: PFIZER INC, Number: 000, 2012] <a href="#">Full Text</a>  <a href="#">Details</a>  <a href="#">Abstract</a> 

[^ Pharmacokinetic - 352](#)

## Quantitative Results

Show/Hide columns 

Parameter	Value (quant)	Unit	Biological Species	Route of administration	Dose	Dosing regimen	Reference
CL (drug clearance)	62	mL/min/kg	Sprague Dawley rat	intravenous administration	3 mg/kg	Single	<a href="#">Flanagan, Mark E.; Blumenkopf, Todd A.; Brissette, William H.; Brown, Matthew F.; Casavant, Jeffrey M.; Shang-Poa, Chang; Doty, Jonathan L.; (...) Whipple, David A.; Changelian, Paul S. [Journal of Medicinal Chemistry, 2010, vol. 53, # 24, p. 8468 - 8484]</a> Full Text  Cited 206 times  Details  Abstract 
CLR (renal clearance)	6.2	mL/min/kg	Sprague Dawley rat	intravenous administration	3 mg/kg	Single	<a href="#">Flanagan, Mark E.; Blumenkopf, Todd A.; Brissette, William H.; Brown, Matthew F.; Casavant, Jeffrey M.; Shang-Poa, Chang; Doty, Jonathan L.; (...) Whipple, David A.; Changelian, Paul S. [Journal of Medicinal Chemistry, 2010, vol. 53, # 24, p. 8468 - 8484]</a> Full Text  Cited 206 times  Details  Abstract 
Vdss	2.6	L/kg	Sprague Dawley rat	intravenous administration	3 mg/kg	Single	<a href="#">Flanagan, Mark E.; Blumenkopf, Todd A.; Brissette, William H.; Brown, Matthew F.; Casavant, Jeffrey M.; Shang-Poa, Chang; Doty, Jonathan L.; (...) Whipple, David A.; Changelian, Paul S. [Journal of Medicinal Chemistry, 2010, vol. 53, # 24, p. 8468 - 8484]</a> Full Text  Cited 206 times  Details  Abstract 
t1/2 el	0.6	hour	Sprague Dawley rat	intravenous administration	3 mg/kg	Single	<a href="#">Flanagan, Mark E.; Blumenkopf, Todd A.; Brissette, William H.; Brown, Matthew F.; Casavant, Jeffrey M.; Shang-Poa, Chang; Doty, Jonathan L.; (...) Whipple, David A.; Changelian, Paul S. [Journal of Medicinal Chemistry, 2010, vol. 53, # 24, p. 8468 - 8484]</a> Full Text  Cited 206 times  Details  Abstract 
Cmax	442	ng/mL	Sprague Dawley rat	oral administration	10 mg/kg	Single	<a href="#">Flanagan, Mark E.; Blumenkopf, Todd A.; Brissette, William H.; Brown, Matthew F.; Casavant, Jeffrey M.; Shang-Poa, Chang; Doty, Jonathan L.; (...) Whipple, David A.; Changelian, Paul S. [Journal of Medicinal Chemistry, 2010, vol. 53, # 24, p. 8468 - 8484]</a> Full Text  Cited 206 times  Details  Abstract 
F (drug bioavailability)	27	%	Sprague Dawley	oral administration	10 mg/kg	Single	<a href="#">Flanagan, Mark E.; Blumenkopf, Todd A.; Brissette, William H.; Brown, Matthew F.; Casavant, Jeffrey M.; Shang-Poa, Chang; Doty, Jonathan L.; (...) Whipple, David A.; Changelian, Paul S. [Journal of Medicinal Chemistry, 2010, vol. 53, # 24, p. 8468 - 8484]</a>

[^ Toxicity/Safety Pharmacology - 4](#)

## Quantitative Results

Show/Hide columns 


pX	Parameter	Value (qual)	Value (quant)	Unit	Biological Species	Action on target	Target	Cell	Bioassay	Dose	Effect	Concomitants	Reference
7.96	IC50		11	nM	human, human	Inhibitor	Tyrosine-protein kinase JAK3 [human]:Wild	T lymphocyte, T lymphocyte	Cell/tumor cell: proliferation/viability/growth	0 $\mu$ M		Solvent: Penicillin-Streptomycin, DMSO; Marker: [3H]-Thymidine;	<a href="#">Flanagan, Mark E.; Blumenkopf, Todd A.; Brissette, William H.; Brown, Matthew F.; Casavant, Jeffrey M.; Shang-Poa, Chang; Doty, (...) Whipple, David A.; Changelian, Paul S. [Jou Medicinal Chemistry, 2010, vol. 53, # 24, p. 84 Full Text  Cited 206 times  Details </a>
7	inhibition rate	Active						U266B1 cell line		0.1 - 100 $\mu$ M	antineoplastic agent	Other compound: dexamethasone, lenalidomide	INSTITUTE FOR MYELOMA & BONE CANCER BERENSON, James R. - WO2015/184087, 2015 <a href="#">Full Text  Details  Abstract </a>
6.49	IC50		324	nM		Inhibitor	Tyrosine-protein kinase JAK2 [human]:Wild	HUO3 cell line	Cell/tumor cell: proliferation/viability/growth	0 $\mu$ M		Solvent: Penicillin-Streptomycin, DMSO; Marker: [3H]-Thymidine;	<a href="#">Flanagan, Mark E.; Blumenkopf, Todd A.; Brissette, William H.; Brown, Matthew F.; Casavant, Jeffrey M.; Shang-Poa, Chang; Doty, (...) Whipple, David A.; Changelian, Paul S. [Jou Medicinal Chemistry, 2010, vol. 53, # 24, p. 84 Full Text  Cited 206 times  Details </a>
1	IC50	>	10000	nM				HFF cell line	Cell/tumor cell: proliferation/viability/growth	0 $\mu$ M		Solvent: Penicillin-Streptomycin, DMSO; Marker: [3H]-Thymidine;	<a href="#">Flanagan, Mark E.; Blumenkopf, Todd A.; Brissette, William H.; Brown, Matthew F.; Casavant, Jeffrey M.; Shang-Poa, Chang; Doty, (...) Whipple, David A.; Changelian, Paul S. [Jou Medicinal Chemistry, 2010, vol. 53, # 24, p. 84 Full Text  Cited 206 times  Details </a>

## Фильтры по биологическим свойствам


Reaxys MedChem Forms	^
 Affinity on target	
 Cell proliferation: inhibition	
 Selectivity Profile	
 Animal models: Tumor xenografts	
 Bioavailability	
 Volume of distribution	
 Absorption (Cmax, Cavg)	
 Caco-2 permeability	
 Caco-2 Active transport	
...	

 Blood-Brain Barrier Penetration (BBB)	
 Cytotoxicity	
 hERG inhibition	
 Cytochrome inhibition (CYP3A4)	
 Metabolism by cytochrome (CYP2D6)	
 Microsomal stability	
 Protein binding (blood, plasma)	
 Cardiotoxicity	
 Bioactivity	
...	


Поиск ингибиторов Aurora A в Reaxys Medicinal Chemistry




Staurosporine;




Pazopanib;




Crizotinib;




Tozasertib;




Danusertib;



Dovitinib;



Alisertib;



PHA-848125;

## ПОИСК СОЕДИНЕНИЙ С ИСПОЛЬЗОВАНИЕМ ЦЕЛЕВОГО ПРОФИЛЯ

Мы можем расширить поиск в RM до всех соединений, которые соответствуют профилю для успешного препарата от шизофрении, осуществив поиск исходя из этих требований

Select how you want to combine the hitsets

 Merge all

 Overlap all

Find all compounds with high activity against 5HT1a, 2a, and D2 receptors

Cancel

---

Combine hitsets Select at least two hitsets for combining 


Query	Temporary result description	Date
	Sort by <input type="text" value="Date"/> 	
<input type="checkbox"/>	Schizophrenia Profile Compounds 38 substances	View Rename Remove 2015-01-21 00:02
<input type="checkbox"/>	'5-hydroxytryptamine 2C receptor' pX LT 6.5 11234 substances	View Rename Remove 2015-01-21 00:01
<input checked="" type="checkbox"/>	'5-hydroxytryptamine 1a receptor' pX GT 7.5 11425 substances	View Rename Remove 2015-01-20 23:56
<input checked="" type="checkbox"/>	'5-hydroxytryptamine 2a receptor' pX GT 7.5 7175 substances	View Rename Remove 2015-01-20 23:48
<input checked="" type="checkbox"/>	'dopamine 2 receptor' pX GT 7.5 5254 substances	View Rename Remove 2015-01-20 23:45

# Мишени и известные препараты от шизофрении в Reaxys Medicinal Chemistry


Для каждого препарата может быть составлен профиль на тепловой карте ниже. Понимание побочных эффектов препарата и его активности может быть получено на основе его активности по отношению к мишеням препаратов от шизофрении и мишеням ответственным за побочные

Legend	5-hydroxytryptamine...	adenoosine a1 receptor	adenoosine a2 receptor	alpha 1 adrenergic...	alpha 1a adrenergic...	alpha 1b adrenergic...	alpha 2 adrenergic...	alpha 2a adrenergic...	alpha 2b adrenergic...	alpha 2c adrenergic...	beta 2 adrenergic r...	beta arrestin 2	cannabinoid 1 recep...	dat	dopamine 1 receptor	dopamine 2 long re...	dopamine 2 receptor	dopamine 2 short r...	dopamine 3 receptor	dopamine 4 receptor	histamine 1 receptor	histamine 2 receptor	histamine 3 receptor	histamine 4 receptor	monoamine oxidase a	monoamine oxidase b	muscarinic acetylch...	muscarinic acetylch...	muscarinic acetylch...								
4- Halperidol	6.4			7.9	6.1	8.2		6	6.5		1		8.2	8.7	6.4	6.3	6.3	6.5			1	6	8.5	10.4	10.2	10.1	10	9	7.2	5.8	4.9				6	6.6	5.3
8- Clozapine	7.8			9.2	8.5	8.7	7.1	9	8.2	7.8	1	8.4	9.3	8.9	7.8	7.6	8.1	8.5		6.3		6	7.6	8.4	8.4	8.2	8.8	8.2	9.6	8.7	6.7	7.1			8.3	9	7.9
3- Risperidone	8.5			9.8	8.4	9		6.6	9.1				9.4	9.3	8.8	8	8	8.8		1		6	8.3	9	9.5	9.5	8.8	8.5	8.6	1					6	6	6.2
1- Sertindole	7.4			10.1	9.5	9		8.5	7.5				9.4	9.4	6.4	6.1	6.3	6.3					7.5	9.2	9.4	8.7	9.4	8	6.8						5.6	5.3	
Ziprazidone	8.9			10.1	8.5	9.2		7.5	8.5				9.3		6.8	6.8	7.3	7.1					8.5	9	8.5	9.2	8.1	7.5	8.2	1					5.3	8	
Amisulpride	1			6.2	6.5	1			7.6		1		5.1	4.8	6.9						1		6	9	9	9.3	9	6	1					1			
11- Quetiapine	6.9			7.5	6.5	6.5		7.4	6.5				7.7	7.4	7.1	1		7.5					8	6.4	8	8.1	8	6	8.5	1	1				5.9	8	6.1
2- Olanzapine	6.3			8.8	8.5	8.5	5.2	8.6	7.5	6.7			8.8	8.1	6.8	6.7	6.7	7.5					8	8.1	8.6	8.2	8.5	7.8	9.4	8.7					8.1	8.7	7.9
7- Aripiprazole	9.4			9.1	9.4	8.1		7.4	8				7.5	7.4	6.9	7.1	6.9	7.4		8.4			1	10.2	9.7	10	9.1	8.6	8.2	8	6.6	8			6	8.1	8.8
3- Paliperidone	6.4			9.6		7.1			8.8						7.7	7.5	8	7.9		1			6.1	8.3	9.8	9.4	10		8					5.4			
Bifeprunox	8			5.4				1																9.4	9.2	10.4	9.4										
(S,S)-Asenapine	8.6			10.2	9.8	10.5		9.6	9.8						8.9								9	9.2	9.5	10.2	9.7	8.9	9	8.2					5		
Lurasidone	8.2			9.3		6.3		9.3							7.3		7.9					2	6.5		9		7.8	7.5	6						6		
olanzapine	6			8.7		8.1		8.3	6.2	6.7			7.2		6.6								7.5		8.1		8.3	7.6	9.4						8.7	8.7	7.8

- Embase максимально полный поиск, которым можно управлять



# ЗАПИСИ ПО ЦИПРОФЛОКСАЦИНУ В EMBASE И PUBMED



PubMed | Ciprofloxacin | Create RSS | Create alert | Advanced

Format: Summary | Sort by: Most Recent | Per page: 20

**Best matches for Ciprofloxacin:**

- [Use of ciprofloxacin during breastfeeding.](#)  
Kaplan YC et al. Can Fam Physician. (2015)
- [Safety and pharmacokinetics of ciprofloxacin dry powder randomized, single-dose, dose-escalation study.](#)  
Stass H et al. J Aerosol Med Pulm Drug Deliv. (2015)
- [PHARMACOKINETICS OF SINGLE-DOSE ORALLY AT CALIFORNIA SEA LIONS \(ZALOPHUS CALIFORNIANUS\).](#)  
Barbosa L et al. J Zoo Wildl Med. (2015)


Switch to our new best match sort order

**Search results**  
Items: 1 to 20 of 25905

Поисковая строка в pubmed:  
"ciprofloxacin"[MeSH Terms] OR  
"ciprofloxacin"[All Fields]

Как видно по ципрофлоксацину в Embase найдено 91 996 записей, в pubmed только 25 905.

Embase®



Results

'ciprofloxacin'/exp OR ciprofloxacin

Search | Mapping | Date | Sources | Fields | Quick limits | EBM | Pub. types

Results Filters

- Expand | Collapse all | Apply
- History | Save | Delete | Print
- #1 'ciprofloxacin'/exp OR ciprofloxacin
- 91,996 results for search #1 | Set
- Results | View | Print | Export


Sources | Drugs

Поисковая строка в EMBASE:  
'ciprofloxacin'/exp OR ciprofloxacin

Согласно Правилам надлежащей практики фармаконадзора ЕС И ЕАЭС для мониторинга литературы по ципрофлоксацину должна использоваться база Embase.

## Embase всеобъемлющий доступ к литературе, критичной для отчетов клинической оценки

Embase® Medline включена в Embase



- Более 32 миллионов публикаций по ЛП
- Около 2.5 миллиона публикаций по теме Medical Devices
- За 2017 год 492136 новых записей по ЛП
- **Более 2700 уникальных журналов, не содержащихся в Medline.**
- 200 наименований, охватывающих биомедицинскую инженерию, биофизику.
- Названия также включают такие области, как кардиология, урология, ортопедия и т.д.
- **Начиная с 2009 года тезисы конференций**
- Уникальная таксономия
- Индексируется вручную профессионалами с биомедицинским образованием
- PICO поисковая форма
- PV Wizard

ПОКРЫТИЕ ТЕЗИСОВ КОНФЕРЕНЦИЙ

САМАЯ СВЕЖАЯ ИНФОРМАЦИЯ

Embase®

РАННИЙ ВЗГЛЯД НА ИССЛЕДОВАНИЯ

Field labels

Abbreviated journal title :ta	CAS registry number :rn
Abstract :ab	Clinical trial number :cn
Accession number :an	CODEN :cd
Article title :ti	Conference date :dc
Author address :ad	Conference editor :ed
Author email :em	Conference location :lc
Author name :au	Conference name :nc
Index term :de	Page range :pg
ISSN :is	Publication date :pd
Issue :ip	Publication type :it
Language of article :la	Publication year :py
Language of summary :ls	Source title :jt
Molecular sequence number :ms	Source type :pt
Original non-English title :tt	Start page :sp

<input type="checkbox"/> Article	<input type="checkbox"/> Erratum
<input type="checkbox"/> Article in Press	<input type="checkbox"/> Letter
<input type="checkbox"/> Conference Abstract	<input type="checkbox"/> Note
<input type="checkbox"/> Conference Paper	<input type="checkbox"/> Review
<input type="checkbox"/> Conference Review	<input type="checkbox"/> Short Survey
<input type="checkbox"/> Editorial	

Publication types

<input type="checkbox"/> Article	1498
<input type="checkbox"/> Review	1024
<input type="checkbox"/> Conference Abstract	931
<input type="checkbox"/> Note	121
<input type="checkbox"/> Letter	71
<input type="checkbox"/> Editorial	66
<input type="checkbox"/> Short Survey	48
<input type="checkbox"/> Conference Paper	45
<input type="checkbox"/> Article in Press	13

> Export

Embase includes conference abstracts dating back to 2009. It currently indexes 7,000+ conferences covering over 2.4 million conference abstracts-advanced information that **can't** be found searching MEDLINE alone.

Доступ к исследования до того, как они опубликованы в статье журнала

- Включает более 7000 конференций и покрывают 2.4 миллиона тезисов

Детальное сравнение EMBASE и MEDLINE

<http://elsevierscience.ru/files/PLS%2520Embase%2520MEDLINE%2520FS%2520WEB%2520RUS.pdf>

**Embase имеет лучшее покрытие контента, опубликованного на языках, отличных от английского...**

Language	Embase (per year)	MEDLINE (per year)	Unique in Embase
English **	1,413,745	623,018	790,727
Chinese	23,798	13,675	10,123
French	12,094	6,170	5,924
Spanish	12,333	4,273	8,060
Japanese	6,703	5,010	1,693
Russian	5,522	3,979	1,543
Portuguese	2,718	1,493	1,225
Polish	1,712	982	730
Turkish	1,534	421	1,113
Korean	364	146	360

[1] Search query: e.g. 'randomized controlled trial'/NOT [31-5-2017]/sd AND [french]/lim

[2] Search query: e.g. (((("1000/1/1"[MeSH Date]:"20exp 17/5/31"[MeSH Date] AND medline[sb]) AND Randomized Controlled Trial[ptyp])) AND french[Language]

...больше РКИ особенно на языках, отличных от английского.

Language	Embase.com	MEDLINE (PubMed)	Embase Advantage	Percent
Chinese	11042	7427	3615	49%
French	3384	2876	508	18%
Spanish	2876	2128	748	35%
Japanese	2139	1237	902	73%
Portuguese	1154	614	540	88%
Polish	575	376	199	53%
Turkish	944	109	835	766%
Korean	193	83	110	133%

[1] Search query: e.g. 'randomized controlled trial'/NOT [31-5-2017]/sd AND [french]/lim

[2] Search query: e.g. (((("1000/1/1"[MeSH Date]:"20exp 17/5/31"[MeSH Date] AND medline[sb]) AND Randomized Controlled Trial[ptyp])) AND french[Language]

Детальное сравнение EMBASE и MEDLINE

<http://elsevierscience.ru/files/PLS%2520Embase%2520MEDLINE%2520FS%2520WEB%2520RUS.pdf>


## Индексирование носителями языка. Установление взаимосвязи между поисковыми терминами

### Поиск по смыслу, а не по словосочетанию

**Тройное индексирование** - это трех уровневое индексирование полного текста статьи.


Состоит из :

- Термина (препарата, заболевание, или медицинское изделие)
- Ключевого подзаголовка (**взаимосвязь**, неблагоприятная реакция лекарственного средства, комбинация лекарств, сравнение лекарств, взаимодействие с лекарственными средствами, лекарственная терапия, неблагоприятный эффект, сравнение препаратов и мед изделий, побочный эффект лекарственной терапии)
- Связанный термин (например, стоматит, гипертония, инсульт, тошнота и т. д)




Устанавливают взаимосвязь «препарат» с «неблагоприятными эффектами» и их «последствиями»

Это термины которые используются в качестве **классификаторов понятий** лекарств, болезней и устройств для уточнения смысла, **обеспечивая очень точное представление о том, что охватывает индексируемый документ.**



# В EMBASE для поиска используется более совершенная таксономия Emtree

Medline >28,000 терминов,  
**Embase >75,000 терминов**  
3,000 специфичных общих терминов и  
по  
медицинским изделиям  
А также в Embase более  
**320,000 синонимов,**



**Vioxx** (синоним) или **rofecoxib** предпочтительный термин

**Heart attack**


**myocardial infarction**

# Поиск с использованием синонимов Embase



Индексация способствует **последовательному и всеобъемлющему поиску информации с помощью Embase**, что значительно расширяет возможности поиска – за счет мощности «соответствия».

Query	Results
'nitrofurantoin'/exp	13,273
'furadantin'/exp	13,273
'ivadantin'/exp	13,273




**Synonyms**

1 (5 nitro 2 furfurylideneamino) hydantoin; 1 [(5 nitrofurfurylidene) amino] hydantoin; 3 (5 furfurylidene) aminohydantoin; 3 (5 nitrofurfurylidene) aminohydantoin; 3 (5 nitrofurfurylidene) aminohydantoin; berkfurin; biofuran; chemiofuran; dantafur; f 30; f30; fua-med; furaben; **furadantini**; furadantin c; furadantin retard; furadantin sodium; furadantin suspension; furadantina; furadantina mc; **furadantine**; furadantine mc; furadantine-mc; furadantoin; furadina; furadoine; furadonin; furadonine; furalan; furanpur; furantocompren; furantoin; furantoina; furantoin; furobactina; furofen; furophen; furophen t; furophen tc; infurin; ituran; **ivadantin**; macrobid; macrodantin; macrodantina; macrofuran; macrofurin; micofurantin; micofurantina; mitrofuratoin; n (5 nitro 2 furfurylidene) 1 aminohydantoin; n (5 nitro furfurylidene) 1 aminohydantoin; n (5 nitrofurfurylidene) aminohydantoin; n toin; nephronex; nierofu; nifurantin; nifuryl; nitro furantoin; nitro macro; nitrofuracin; nitrofuradantoin; nitrofurantine; nitrofurantoin (monohydrate/macrocystals); nitrofurantoin macrocrystal; nitrofurantoin macrocrystalline; nitrofurantoin macrocrystals; nitrofurantoin plus nitrofurantoin, macrocrystalline; nitrofurantoin sodium; nitrofurantoin, macrocrystalline; nitrofurantoine; nitrofurin; novofuran; nsc 2107; nsc2107; orafuran; parfuran; phenurin; potassium furagin; ralodantin; trocurine; urantin; uro tablinen; uro-tablinen; urodil; urodin; urofuran; urolong; urotablinen; urotoina; uvamin; uvamin retard

### Embase vs Medline

Запрос "Drug"  
**Embase®** 10,693,587  
**MEDLINE** 5,357,163  
 Дата запроса 12.10.2018



Embase®

MEDLINE

1. Охват документов (журналы и конференции)
2. Информация на языках отличных от английского
3. Разумная индексация носителями языка и (взаимосвязь между терминами)
4. Таксономия
5. Синонимы

Детальное сравнение EMBASE и MEDLINE

<http://elsevierscience.ru/files/PLS%2520Embase%2520MEDLINE%2520FS%2520WEB%2520RUS.pdf>

# Embase рекомендуется регулируемыми органами и органами власти.



EUROPEAN MEDICINES AGENCY  
SCIENCE MEDICINES HEALTH



**ЦЭККМП**

Федеральное государственное бюджетное учреждение  
«**Центр экспертизы и контроля качества медицинской помощи**»  
Министерства здравоохранения Российской Федерации



EUROPEAN MEDICINES AGENCY  
SCIENCE MEDICINES HEALTH

Committee for Medicinal Products for  
Veterinary Use (CVMP)



THE JOANNA BRIGGS INSTITUTE  
*Better evidence. Better outcomes.*



(CFDA Drug Evaluation Guideline, draft)  
**药品文献评价指导原则**  
国家食品药品监督管理局药品评价中心  
(征求意见稿 2009.1)

**ЕЭК**

ЕВРАЗИЙСКАЯ  
ЭКОНОМИЧЕСКАЯ  
КОМИССИЯ

**NICE** National Institute for  
Health and Care Excellence

# Поиск информации

Embase®

Search

Emtree

Journals

Results

My tools

Alexey Moiseev

Logout



## Results

Выбрать язык | ▼

'bowel disease'

Search &gt;

Mapping ▼

Date ▼

Sources ▼

Fields ▼

Quick limits ▼

EBM ▼

Pub. types ▼

Search tips ▼

### Results Filters

+ Expand — Collapse all

Apply &gt;

Sources ▼

Drugs ▼

Diseases ▼

Devices ▼

Floating Subheadings ▼

Age ▼

 History

Save | Delete | Print view | Export | Email

Combine &gt;

using  And  Or

^ Collapse

 #2 'bowel disease'

86,081

 #1 'tofacitinib'/exp OR tofacitinib

4,285

86,081 results for search #2



Set email alert



Set RSS feed



Search details

new



Index miner

 Results

View | Print | Export | Email | Order | Add to Clipboard

1 — 100



Select number of items ▼

Selected: 0 (clear)

Show all abstracts |

Sort by:

 Relevance Publication Year Entry Date 1 Treatment adherence in inflammatory bowel disease patients from Argentina: A multicenter study

Lasa J., Correa G., Fuxman C., Garbi L., Linares M.E., Lubrano P., Rausch A., Toro M., Yantorno M., Zubiaurre I., Peyrin-Biroulet L., Olivera P.

Gastroenterology Research and Practice 2020 2020 Article Number 4060648 Cited by: 0

Embase

▼ Abstract

▼ Index Terms

&gt; View Full Text

new

Similar records &gt;

- Операторы AND, OR, AND NOT для объединения полей поиска

# Поиск информации

'bowel disease'

**Search >** Mapping ▾ Date ▲ Sources ▾ Fields ▾ Quick limits ▾ EBM ▾ Pub. types ▾ Languages ▾ Gender ▾ Age ▾ Animal ▾

Date limits

Publication Years from: 2020 ▾ to 2020 ▾

Records added to Embase (including end date): 01-01-2016 to 31-12-2016 📅  
(dd-mm-yyyy to dd-mm-yyyy)

- Ограничители временного охвата

- Sources
- Drugs
- Diseases
- Devices
- Floating Subheadings
- Age
- Gender
- Study types
- Publication types
- Journal titles
- Publication years
- Authors
- Conference Abstracts
- Drug Trade Names
- Drug Manufacturers
- Device Trade Names
- Device Manufacturers

Apply &gt;

 #2 'bowel disease' 86,081 #1 'tofacitinib'/exp OR tofacitinib 4,285430 results for search #3 Set email alert Set RSS feed Search details new Index miner Results View | Print | Export | Email | Order | Add to Clipboard

1 — 100



Select number of items Selected: 0 (clear)

Show all abstracts | Sort by:  Relevance  Publication Year  Entry Date

- 1 Vedolizumab-induced de novo extraintestinal manifestations  
Diaz L.I., Keihanian T., Schwartz I., Kim S.B., Calmet F., Quintero M.A., Abreu M.T.  
*Gastroenterology and Hepatology* 2020 16:2 (75-81) Cited by: 0  
Embase Abstract Index Terms new Similar records >
- 2 Down the line from genome-wide association studies in inflammatory **bowel disease**: The resulting clinical benefits and the outlook for the future  
Spekhorst L.M., Visschedijk M.C., Weersma R.K., Festen E.A.  
*Expert Review of Clinical Immunology* 2015 11:1 (33-44) Cited by: 11  
Embase MEDLINE Abstract Index Terms > View Full Text new Similar records >
- 3 The Complex Interplay Between Inflammatory **Bowel Disease** and Malignancy  
Kimmel J., Axelrad J.  
[In Process] *Current Gastroenterology Reports* 2020 22:3 Article Number 13 Cited by: 0  
Embase MEDLINE Abstract Index Terms > View Full Text new Similar records >
- 4 Evolving primary and secondary endpoints in randomized controlled trials leading to approval of biologics and small molecules in IBD: an historical perspective  
Allen P.B., Bonovas S., Danese S., Peyrin-Biroulet L.  
*Expert Opinion on Biological Therapy* 2020 20:2 (151-161) Cited by: 0  
Embase MEDLINE Abstract Index Terms > View Full Text new Similar records >
- 5 First-Line Biologics or Small Molecules in Inflammatory **Bowel Disease**: a Practical Guide for the Clinician  
Chang S., Hudesman D.  
*Current Gastroenterology Reports* 2020 22:2 Article Number 7 Cited by: 0  
Embase MEDLINE Abstract Index Terms > View Full Text new Similar records >

# Применение инструмента PICO

## Пример из доказательной клинической практики

**Сценарий :** необходимо составить отчет о клинической оценке препарата **Verberine**

**Цель:** Собрать информацию необходимую для успешного представления в регулирующие органы, которая включает:

- **Клиническая эффективность препарата**
- **Сравнение с другими существующими препаратами**
- **Безопасность препараты - поиск побочного действия**

Бесплатный вебинар «Как писать систематические обзоры с использованием поискового инструмента PICO»

<https://www.brighttalk.com/webcast/16527/307607>

# Сбор информации о клинической эффективности

('berberine'/exp OR 'berberin' OR 'berberine' OR 'berberine hydrochloride' OR 'berberinium chloride' OR 'umbellatine') AND ('randomized controlled trial'/exp OR 'controlled trial, randomized' OR 'randomised controlled study' OR 'randomised controlled trial' OR 'randomized controlled study' OR 'randomized controlled trial' OR 'trial, randomized controlled' OR 'systematic review'/exp OR 'review, systematic' OR 'systematic review' OR 'meta analysis'/exp OR 'analysis, meta' OR 'meta analysis' OR 'meta-analysis' OR 'metaanalysis')

Intervention

berberine /exp + 5 synonyms :all

Clear field

Study design (or miscellaneous)

randomized controlled trial /exp + 6 synonyms :all OR systematic review /exp + 2 synonyms :all OR meta analysis /exp + 4 synonyms :all

Clear field

Results Filters

+ Expand — Collapse all Apply

Sources

Drugs

Diseases

Devices

Floating Subheadings

Age

Gender

Study types

Publication types

Journal titles

Publication years

History

Expand

173 results for search #14 Set email alert Set RSS feed Search details Index miner

Results View | Print | Export | Email | Order | Add to Clipboard 1 — 173

Select number of items Selected: 0 (clear) Show all abstracts | Sort by: Relevance Publication Year Entry Date

- 1 Are personalized tongxie formula based on diagnostic analyses more effective in reducing IBS symptoms?—A randomized controlled trial  
 Wang Y., Fan H., Qi X., Lai Y., Yan Z., Li B., Tang M., Huang D., Li Z., Chen H., Zhu Q., Luo C., Chen X., Fen J., Jiang Z., Zheng L., Liu X., Tang Q., Zuo D., Ye J., Yang Y., Huang H., Tang Z., Lu W., Xiao J.  
*Complementary Therapies in Medicine* 2018 40 (95-105) Cited by: 0  
 Embase Abstract Index Terms View Full Text Similar records
- 2 Atheroprotective effects and molecular targets of bioactive compounds from traditional Chinese medicine  
 Qiao L., Chen W.  
*Pharmacological Research* 2018 135 (212-229) Cited by: 0  
 Embase Abstract Index Terms View Full Text Similar records
- 3 Berberine reduces the inflammatory reaction in chronic sinusitis with nasal polyps  
 Li G., Zhao H., Zhu D., Sun Q.  
*Allergy: European Journal of Allergy and Clinical Immunology* 2018 73 Supplement 105 (S72-)  
 Embase Abstract Index Terms View Full Text Similar records

Бесплатный вебинар как писать систематические обзоры с использованием поискового инструмента PICO <https://www.brighttalk.com/webcast/16527/307607>

# 1.1 Оценка данных по безопасности с помощью Embase

Уточнение  
инструкции по  
применению

92,757 results for search #6

Results View | Print | Export | Email | Order | Add to Clipboard

Key subheadings

- adverse drug reaction 3992
- drug combination 8584
- drug comparison 9594
- drug interaction 2104
- drug therapy 33714

Adverse drug reaction

type any adverse drug reaction (autocomplete)

- all
- nausea 136
- diarrhea 132
- unspecified side effect 128
- drug hypersensitivity 83
- vomiting 81
- rash 76
- headache 75
- dizziness 70
- drug eruption 67
- gastrointestinal symptom 62
- QT prolongation 60
- tendinitis 58
- urticaria 57
- Stevens Johnson syndrome 56
- toxic epidermal necrolysis 46
- tendon rupture 42
- anaphylaxis 40
- arthralgia 39
- abdominal pain 38
- insomnia 37
- hypoglycemia 35
- photosensitivity 34

Export Apply >

Используем тройное индексирование которое связывает «препарат» с «неблагоприятными эффектами» и «их последствиями». позволяет за несколько секунд найти 3992 статьи, в которых описаны 800+ ADR ципрофлоксацина

# 1.2 Оценка данных по эффективности с помощью Embase

## Сбор информации для сравнения препарата с другими препаратами

Quick **PICO** PV Wizard Advanced Drug Disease Device Article Authors

3 synonyms

for placebo

ALL

placebo

placebo gel

placebos

Population

e.g. diabetes

Intervention

berberine /exp + 5 synonyms :all

Comparison

placebo /exp + 3 synonyms :all

Default search strategy

/mj  /de  /exp  /br

Clear field

Clear field

Results Filters

+ Expand — Collapse all

Apply >

Sources

Drugs

Diseases

Devices

Floating Subheadings

Age

Gender

Study types

Publication types

Journal titles

Publication years

History

Expand

173 results for search #14 Set email alert Set RSS feed Search details Index miner

Results View | Print | Export | Email | Order | Add to Clipboard 1 — 173

Select number of items Selected: 0 (clear)

Show all abstracts | Sort by:  Relevance  Publication Year  Entry Date

- 1 Are personalized tongxie formula based on diagnostic analyses more effective in reducing IBS symptoms?—A randomized controlled trial  
Wang Y., Fan H., Qi X., Lai Y., Yan Z., Li B., Tang M., Huang D., Li Z., Chen H., Zhu Q., Luo C., Chen X., Fen J., Jiang Z., Zheng L., Liu X., Tang Q., Zuo D., Ye J., Yang Y., Huang H., Tang Z., Lu W., Xiao J.  
*Complementary Therapies in Medicine* 2018 40 (95-105) Cited by: 0  
Embase Abstract Index Terms > View Full Text Similar records >
- 2 Atheroprotective effects and molecular targets of bioactive compounds from traditional Chinese medicine  
Qiao L., Chen W.  
*Pharmacological Research* 2018 135 (212-229) Cited by: 0  
Embase Abstract Index Terms > View Full Text Similar records >
- 3 **Berberine** reduces the inflammatory reaction in chronic sinusitis with nasal polyps  
Li G., Zhao H., Zhu D., Sun Q.  
*Allergy: European Journal of Allergy and Clinical Immunology* 2018 73 Supplement 105 (S72-)  
Embase Abstract Index Terms > View Full Text Similar records >

<https://www.embase.com/#/picoSearch>

## 1.3 Оценка данных по клинической эффективности с помощью Embase

('berberine'/exp OR 'berberin' OR 'berberine' OR 'berberine hydrochloride' OR 'berberinium chloride' OR 'umbellatine') AND ('randomized controlled trial'/exp OR 'controlled trial, randomized' OR 'randomised controlled study' OR 'randomised controlled trial' OR 'randomized controlled study' OR 'randomized controlled trial' OR 'trial, randomized controlled' OR 'systematic review'/exp OR 'review, systematic' OR 'systematic review' OR 'meta analysis'/exp OR 'analysis, meta' OR 'meta analysis' OR 'meta-analysis' OR 'metaanalysis')

Intervention

berberine /exp + 5 synonyms :all

Clear field

Study design (or miscellaneous)

randomized controlled trial /exp + 6 synonyms :all OR systematic review /exp + 2 synonyms :all OR meta analysis /exp + 4 synonyms :all

Clear field

Results Filters

+ Expand - Collapse all Apply

Sources

Drugs

Diseases

Devices

Floating Subheadings

Age

Gender

Study types

Publication types

Journal titles

Publication years

History

173 results for search #14 Set email alert Set RSS feed Search details Index miner

Results View | Print | Export | Email | Order | Add to Clipboard 1 — 173

Select number of items Selected: 0 (clear) Show all abstracts | Sort by: Relevance Publication Year Entry Date

1 Are personalized tongxie formula based on diagnostic analyses more effective in reducing IBS symptoms?—A randomized controlled trial  
Wang Y., Fan H., Qi X., Lai Y., Yan Z., Li B., Tang M., Huang D., Li Z., Chen H., Zhu Q., Luo C., Chen X., Fen J., Jiang Z., Zheng L., Liu X., Tang Q., Zuo D., Ye J., Yang Y., Huang H., Tang Z., Lu W., Xiao J.  
*Complementary Therapies in Medicine* 2018 40 (95-105) Cited by: 0  
Embase Abstract Index Terms View Full Text Similar records

2 Atheroprotective effects and molecular targets of bioactive compounds from traditional Chinese medicine  
Qiao L., Chen W.  
*Pharmacological Research* 2018 135 (212-229) Cited by: 0  
Embase Abstract Index Terms View Full Text Similar records

3 Berberine reduces the inflammatory reaction in chronic sinusitis with nasal polyps  
Li G., Zhao H., Zhu D., Sun Q.  
*Allergy: European Journal of Allergy and Clinical Immunology* 2018 73 Supplement 105 (S72-)  
Embase Abstract Index Terms View Full Text Similar records

Бесплатный вебинар как писать систематические обзоры с использованием поискового инструмента PICO  
<https://www.brighttalk.com/webcast/16527/307607>

# Анализ результатов. Извлеченные данные. Сжатое резюме статьи

Did you miss the last webinar about the French literature module? [Watch it now!](#)

Embase®

Search Emtree Journals Results My tools Alexey Moiseev Logout (1) ?

← Back to Results

Export ↓

Send ✉

Add to clipboard 📄

Full record

Showing # 1 of 3,994

Translated Title

## Guidelines for the management of paediatric cholera infection: a systematic review of the evidence

**Paediatrics and International Child Health** 2018 **38** Supplement 1 (S16 - S31)

Translated Abstract

Background: *Vibrio cholerae* is a highly motile Gram-negative bacterium which is responsible for 3 million cases of diarrhoeal illness and up to 100,000 deaths per year, with an increasing burden documented over the past decade. Current WHO guidelines for the treatment of paediatric cholera infection (tetracycline 12.5 mg/kg four times daily for 3 days) are based on data which are over a decade old. In an era of increasing antimicrobial resistance, updated review of the appropriate empirical therapy for cholera infection in children (taking account of susceptibility patterns, cost and the risk of adverse events) is necessary. Methods: A systematic review of the current published literature on the treatment of cholera infection in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) was undertaken. International clinical guidelines and studies pertaining to adverse effects associated with treatments available for cholera infection were also reviewed. Results: The initial search produced 256 results, of which eight studies met the inclusion criteria. Quality assessment of the studies was performed as per the Grading of Recommendations Assessment, Development and Evaluation guidelines. Conclusions: In view of the changing non-susceptibility rates worldwide, empirical therapy for cholera infection in paediatric patients should be changed to single-dose azithromycin (20 mg/kg), a safe and effective medication with ease of administration. Erythromycin (12.5 mg/kg four times daily for 3 days) exhibits similar bacteriological and clinical success and should be listed as a second-line therapy. Fluid resuscitation remains the cornerstone of management of paediatric cholera infection, and prevention of infection by promoting access to clean water and sanitation is paramount.

© 2018 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group.

Similar records 🔍

Full text on publisher's website ↗

Print record 🖨

Search more from author:

[Williams P.C.M.](#)

[Berkley J.A.](#)

Show all authors (2) >

📄 Drug Terms

Show all subheadings ▾

azithromycin %, chloramphenicol %, **ciprofloxacin %**, cotrimoxazole %, doxycycline %, erythromycin %, norfloxacin %, ofloxacin %, tetracycline %, zinc %

**cotrimoxazole** ✕  
Key Subheadings:  
drug therapy  
cholera

Подзаголовки

+ Expand — Collapse all Apply >

92,757 results for search #6 Set email alert Set RSS feed Search details Index miner

Sources

Drugs

- ciprofloxacin Details ▶ 89525
- gentamicin Details ▶ 25758
- cotrimoxazole Details ▶ 20928
- antibiotic agent Details ▶ 20708
- amikacin Details ▶ 17010
- ceftazidime Details ▶ 16785
- ampicillin Details ▶ 16571
- vancomycin Details ▶ 16432
- ceftriaxone Details ▶ 15468

Diseases

Devices

Floating Subheadings

Age

Gender

Study types

Publication types

Journal titles

Publication years

Authors

Conference Abstracts

Results View | Print | Export | Email | Order | Add to Clipboard

Key subheadings

- adverse drug reaction 3992
- drug combination 8584
- drug comparison 9594
- drug interaction 2104
- drug therapy 33714

Adverse drug reaction

type any adverse drug reaction (autocomplete)

- all
- nausea 136
- diarrhea 132
- unspecified side effect 128
- drug hypersensitivity 83
- vomiting 81
- rash 76
- headache 75
- dizziness 70
- drug eruption 67
- gastrointestinal symptom 62
- QT prolongation 60
- tendinitis 58
- urticaria 57
- Stevens Johnson syndrome 56
- toxic epidermal necrolysis 46
- tendon rupture 42
- anaphylaxis 40
- arthralgia 39
- abdominal pain 38
- insomnia 37
- hypoglycemia 35
- photosensitivity 34

3 Shiga toxin  
Sidnu H., O'Co  
Science of the T  
Embase

4 Photolysis  
Timm A., Bor  
Science of the T  
Embase MED

5 Effects of  
Gomes M.P., R  
Science of the T  
Embase

6 Bioavailabi  
Sidnu H., O'Co  
Science of the T  
Embase MED


7 Antibiotics

Export Apply >

Используем тройное индексирование которое связывает «препарат» с «неблагоприятными эффектами» и «их последствиями». позволяет за несколько секунд найти 3992 статьи, в которых описаны 800+ ADR ципрофлоксацина

# Тройное индексирование

- **Тройное индексирование** это трехуровневая индексация полного текста статьи, и она состоит из:
  - Понятие (лекарство, м или болезнь)
  - Ключевой подзаголовок(взаимоотношение)
  - Связанное понятие (например стоматит, гипертония, тошнота и т. д..)
- Тройная индексация началась в первом квартале 2007 года для **лекарств** (лекарственная терапия со второго квартала 2009 года). Мед. изделия появились во втором квартале 2014 года. Недавно были введены два новых подзаголовка лекарственных препаратов по **фармаконадзору**.



**Manually Extracted Semantic Relationships**

---

# Поиск информации о лечении рака молочной железы с помощью Everolimus

Тройные ссылки:

Извлеченные вручную семантические отношения

- лекарства
- лекарство и заболевание
- мед. изделие
- мед. изделие и заболевание

Поисковая строка:

'everolimus'/'drug therapy'/'breast cancer'

The screenshot displays a search interface with several panels:

- Drugs:** A list of drugs with checkboxes and counts. 'everolimus' is highlighted with a count of 24798. Other drugs include rapamycin (6821), sunitinib (4473), unclassified drug (4023), temsirolimus (3990), sorafenib (3954), bevacizumab (3837), tacrolimus (3809), and cyclosporine (3634). There is a '+ More' button and an 'Export' link.
- Key subheadings:** A list of subheadings with checkboxes and counts. 'drug therapy' is highlighted with a count of 10825. Other subheadings include adverse drug reaction (2855), drug combination (4036), drug comparison (1479), drug interaction (585), special situation for pharmacovigilance (69), and unexpected outcome of drug treatment (13).
- Drug therapy:** A list of drug therapy categories with checkboxes and counts. 'breast cancer' is highlighted with a count of 856. Other categories include all (1220), kidney carcinoma (1220), advanced cancer (643), neuroendocrine tumor (469), kidney metastasis (449), pancreas islet cell tumor (365), kidney graft rejection (351), liver cell carcinoma (319), coronary artery disease (303), metastatic breast cancer (251), acute graft rejection (208), renal cell carcinoma (208), metastasis (207), graft rejection (191), stomach cancer (175), cardiac graft rejection (167), tuberous sclerosis (163), kidney cancer (160), subependymal giant cell astrocytoma (149), liver graft rejection (144), non small cell lung cancer (144), and glioblastoma (131). There is an 'Export' button and an 'Apply' button.

Below the subheadings, there is a section for 'Select number of items' with a dropdown menu and a 'Selected: 0 (clear)' indicator. It shows four items with checkboxes and titles:

- 1 Defective homologous re...  
Gröschel S., Hübschmann D., Richter D., Reisinger E., Pfütze K. *Nature Communications* 2019 10:1-10
- 2 Downstaging Locally Adv...  
Wong M., Kim J., George B., Eriks *Journal of Surgical Research* 2019
- 3 PAK4 regulates stemness...  
Santiago-Gómez A., Kedward T., *Cancer Letters* 2019 458 (66-75) C
- 4 Efficacy and acceptability...  
Zhang T., Feng F., Yao Y., Qi L., T *Journal of Cellular Physiology* 2019

# Анализ результатов. Экономим время на чтение статей и документов. Используем извлеченные данные

Did you miss the last webinar about the French literature module? [Watch it now!](#)

Embase®

Search Emtree Journals Results My tools Alexey Moiseev Logout (1) ?

← Back to Results

Export ↓

Send ✉

Add to clipboard 📄

Full record

Showing # 1 of 3,994

Translated Title

## Guidelines for the management of paediatric cholera infection: a systematic review of the evidence

Paediatrics and International Child Health 2018 38 Supplement 1 (S16 - S31)

Translated Abstract

Background: *Vibrio cholerae* is a highly motile Gram-negative bacterium which is responsible for 3 million cases of diarrhoeal illness and up to 100,000 deaths per year, with an increasing burden documented over the past decade. Current WHO guidelines for the treatment of paediatric cholera infection (tetracycline 12.5 mg/kg four times daily for 3 days) are based on data which are over a decade old. In an era of increasing antimicrobial resistance, updated review of the appropriate empirical therapy for cholera infection in children (taking account of susceptibility patterns, cost and the risk of adverse events) is necessary. Methods: A systematic review of the current published literature on the treatment of cholera infection in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) was undertaken. International clinical guidelines and studies pertaining to adverse effects associated with treatments available for cholera infection were also reviewed. Results: The initial search produced 256 results, of which eight studies met the inclusion criteria. Quality assessment of the studies was performed as per the Grading of Recommendations Assessment, Development and Evaluation guidelines. Conclusions: In view of the changing non-susceptibility rates worldwide, empirical therapy for cholera infection in paediatric patients should be changed to single-dose azithromycin (20 mg/kg), a safe and effective medication with ease of administration. Erythromycin (12.5 mg/kg four times daily for 3 days) exhibits similar bacteriological and clinical success and should be listed as a second-line therapy. Fluid resuscitation remains the cornerstone of management of paediatric cholera infection, and prevention of infection by promoting access to clean water and sanitation is paramount.

© 2018 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group.

Similar records 🔍

Full text on publisher's website ↗

Print record 🖨

Search more from author:

Williams P.C.M.

Berkley J.A.

Show all authors (2) >

📄 Drug Terms

## Извлеченные данные

Show all subheadings ▾

azithromycin %, chloramphenicol %, ciprofloxacin %, cotrimoxazole %, doxycycline %, erythromycin %, norfloxacin %, ofloxacin %, tetracycline %, zinc %

cotrimoxazole ✕  
Key Subheadings:  
drug therapy  
cholera

Подзаголовки



1.4 Мониторинг соотношения «польза–риск» fenspiride с помощью Embase/PV Wizard  
Оценка статистики публикаций о ADR в научной литературе

Embase®

Search Emtree Journals **Results** My tools Register

Results filters

+ Expand - Collapse all Apply >

- Sources
- Drugs
- Diseases
- Devices
- Floating Subheadings
- Age
- Gender
- Study types
- Publication types
- Journal titles
- Publication years 
  - 2018 3
  - 2017 3
  - 2016 3
  - 2015 3
  - 2014 2
  - 2013 3
  - 2012 1
  - 2011 5


History

86 results for search #4 [Set email alert](#) [Set RSS feed](#) [Search details](#) [Index miner](#)

Results View | Print | Export | Email | Order | Add to Clipboard

Select number of items Selected: 0 (clear) Show all abstracts | Sort by:  Relevance  Publication

- 1 New approach for determination of the degradation products of fenspiride hydrochloride found in oral liquid formulations  
Cioroiu B.I., Caba I.C., Prisăcaru I., Cioroiu M.E., Lazar M.I., Niculaea M.  
*Biomedical Chromatography* 2018 32:5 Article Number e4176 Cited by: 0  
Embase MEDLINE  Abstract  Index Terms > View Full Text
- 2 Search for narcotics by urine drug testing – suspected cross-reaction between fentanyl and fenspiride  
Chappuy M., Berger-Vergiat A., Cohen S., Ragonnet D., Boucher A.  
*Toxicologie Analytique et Clinique* 2018 30:1 (69-74) Cited by: 0  
Embase  Abstract  Index Terms > View Full Text
- 3 Teen driving education in a paediatric emergency department  
Spears G., Schoen B., Maloney L., Smelcer J., Thompson T., Remington E., Nichols M., King W., Monroe K.  
*Journal of Investigative Medicine* 2018 66:2 (431-)  
Embase  Abstract  Index Terms > View Full Text
- 4 The use of fenspiride for the combined treatment of exacerbation of chronic laryngitis  
Ryabova M.A.  
*Vestnik otorinolaringologii* 2017 82:6 (66-69) Cited by: 0  
MEDLINE [No abstract available]  Index Terms > View Full Text
- 5 Analysis of molecular aberrations associated with copd in patients with lung cancer  
Tokar T., Vucic E., Pastrello C., Lam W., Jurisica I.  
*Journal of Thoracic Oncology* 2017 12:1 Supplement 1 (S1150-S1151)  
Embase  Abstract  Index Terms



# Извлеченные данные по Embase.Экспорт в csv

The screenshot displays the Embase search results page with several filters and an export dialog box. The main interface includes a search bar, navigation tabs (Search, Emtree, Journals, Results), and a 'Results' section. The 'Gender' filter shows 46 males and 44 females. The 'Age' filter lists categories like Child (1-12), Preschool child (1-6), School child (7-12), Adolescent, Young adult, Adult, Middle aged, Aged, and Very elderly. The 'Publication years' filter ranges from 2010 to 2018. The 'Drug Trade Names' filter lists various drugs with their respective counts. The 'Drug Manufacturers' filter lists companies like Servier, Sigma, Biopharma, and Boehringer Ingelheim. An 'Export' dialog box is open, showing options to export as HTML, Text, or CSV file, with the CSV option selected.

**Export Dialog Box:**

Export as:

- HTML file Formatted, includes all sub-searches
- Text file (export.txt) Plain text format
- CSV file (export.csv) Comma separated

Check to expand combined queries

Buttons: Cancel > Export >

**Gender Filter:**

- Male: (46)
- Female: (44)

**Age Filter:**

- Child (1-12) 14
- Preschool child (1-6) 1
- School child (7-12) 1
- Adolescent 14
- Young adult 0
- Adult 43
- Middle aged 22
- Aged 23
- Very elderly 0

**Publication years Filter:**

- 2018 3
- 2017 3
- 2016 3
- 2015 3
- 2014 2
- 2013 3
- 2012 1
- 2011 5
- 2010 3

**Drug Trade Names Filter:**

- pneumorel 14
- eurespal 5
- bricanyl 2
- bronchodual 2
- euphylline 2
- imovane 2
- pneumorel 80 2
- serevent 2
- theostat 2

**Drug Manufacturers Filter:**

- Servier 10
- Sigma 2
- biopharma 1
- Biopharma 1
- Boehringer Ingelheim 1
- erregierre 1
- lab biopharma 1
- Merck 1
- Polfa 1

# Everolimus – list of all *on-label* and *off-label* use indexed on Embase

**Drugs**

- everolimus **Details ▶ 24809**
- rapamycin **Details ▶ 6948**
- sunitinib **Details ▶ 4526**
- unclassified drug **Details ▶ 4134**
- temsirolimus **Details ▶ 4014**
- sorafenib **Details ▶ 3990**
- bevacizumab **Details ▶ 3875**
- tacrolimus **Details ▶ 3854**
- cyclosporine **Details ▶ 3664**
- + More** > Export

**Diseases** ▼

**Devices** ▼

**Floating Subheadings** ▼

**Age** ▼

**Gender** ▼

**Study types** ▼

**Publication types** ▼

**Journal titles** ▼

**Publication years** ▼

**Authors** ▼

**Conference Abstracts** ▼

**Key subheadings**

- adverse drug reaction 2855
- drug combination 4036
- drug comparison 1480
- drug interaction 585
- drug therapy 10826**
- special situation for pharmacovigilance 70
- unexpected outcome of drug treatment 13

---

2 **Downstaging Locally Adv**  
Wong M., Kim J., George B., Eriks  
*Journal of Surgical Research* 2019  
Embase MEDLINE ▼ Abstracts

3 **AKT and ERK dual inhibiti**  
Cao Z., Liao Q., Su M., Huang K.,  
*Cancer Letters* 2019 459 (30-40) C  
Embase MEDLINE ▼ Abstracts

4 **Abluminal biodegradable**  
from the COMPARE II tria  
Paradies V., Vlachojannis G.J., Ro  
[In Process] *International Journal* c  
Embase MEDLINE ▼ Abstracts

5 **Two-year clinical outcom**  
De Carlo M., Testa L., Leoncini M  
[In Process] *International Journal* c  
Embase MEDLINE ▼ Abstracts

**Drug therapy**

type any drug therapy (autocomplete) x

- all
- kidney carcinoma 1220
- breast cancer 856
- advanced cancer 643
- neuroendocrine tumor 469
- kidney metastasis 449
- pancreas islet cell tumor 365
- kidney graft rejection 351
- liver cell carcinoma 319
- coronary artery disease 303
- metastatic breast cancer 251
- acute graft rejection 208
- renal cell carcinoma 208
- metastasis 207
- graft rejection 191
- stomach cancer 175
- cardiac graft rejection 167
- tuberous sclerosis 163
- kidney cancer 161
- subependymal giant cell astrocytoma 149
- liver graft rejection 144
- non small cell lung cancer 144
- glioblastoma 131

**Export** Apply >

# Связь между годом одобрения и записями, сообщающими о прямой связи между лекарством и показаниями

	Kidney cancer	Pancreatic Neuroendocrine Tumor	Breast cancer	Neuroendocrine tumor	Tuberous Sclerosis	
2008	9	2	2			
2009	124	3	36	21	2	
2010	158	8	64	32	3	
2011	215	26	66	29	11	
2012	193	80	145	30	10	# published articles for everolimus per year
2013	170	84	165	36	26	
2014	115	40	144	30	15	
2015	103	57	108	37	28	
2016	154	58	114	45	18	

Является ли туберозный склероз следующим применением для одобрения Everolimus?

# Everolimus for Tuberous Sclerosis in Clinical Trials

#1: 'Everolimus'/drug therapy'/tuberous sclerosis'

The screenshot shows a search interface with three main panels:

- Drugs:** A list of drugs with checkboxes and detail counts:
 

<input type="checkbox"/>	everolimus	Details ▶	24809
<input type="checkbox"/>	rapamycin	Details ▶	6948
<input type="checkbox"/>	sunitinib	Details ▶	4526
<input type="checkbox"/>	unclassified drug	Details ▶	4134
<input type="checkbox"/>	temsirolimus	Details ▶	4014
<input type="checkbox"/>	sorafenib	Details ▶	3990
<input type="checkbox"/>	bevacizumab	Details ▶	3875
- Key subheadings:** A list of subheadings with checkboxes and counts:
 

<input type="checkbox"/>	adverse drug reaction	2855
<input type="checkbox"/>	drug combination	4036
<input type="checkbox"/>	drug comparison	1480
<input type="checkbox"/>	drug interaction	585
<input checked="" type="checkbox"/>	drug therapy	10826
<input type="checkbox"/>	special situation for pharmacovigilance	70
<input type="checkbox"/>	unexpected outcome of drug treatment	13
- Drug therapy:** A search box with the text "type any drug therapy (autocomplete)" and a list of therapy types:
 

<input type="checkbox"/>	all	
<input type="checkbox"/>	cardiac graft rejection	167
<input checked="" type="checkbox"/>	tuberous sclerosis	163
<input type="checkbox"/>	kidney cancer	161
<input type="checkbox"/>	subependymal giant cell astrocytoma	149

#2: 'Everolimus'/clinical trial'

Embase query:  
'Everolimus'/drug therapy'/  
'tuberous sclerosis' AND  
'Everolimus'/clinical trial'

The screenshot shows the "Drug Search" interface with the following elements:

- Navigation:** Quick, PICO, PV Wizard, Advanced, **Drug**, Disease, Device, Article, Authors.
- Search Input:** A search box containing the text "'everolimus'".
- Search Controls:** Search >, Mapping ▼, Date ▼, Sources ▼, Drug fields ▼, **Drug subheadings ▲**, Routes ▼, Quick limits ▼, EBM ▼, Pub. types ▼.
- Subheadings:** A list of subheadings with checkboxes:
 

<input type="checkbox"/>	Adverse drug reaction	<input type="checkbox"/>	Drug development	<input type="checkbox"/>	Pharmacoeconomics
<input checked="" type="checkbox"/>	Clinical trial	<input type="checkbox"/>	Drug dose	<input type="checkbox"/>	Pharmacokinetics
<input type="checkbox"/>	Drug administration	<input type="checkbox"/>	Drug interaction	<input type="checkbox"/>	Pharmacology

## ОТФИЛЬТРОВЫВАЕМ ИССЛЕДОВАНИЯ НА ЖИВОТНЫХ

Embase® Search Entree Journals Results My tools Register Login (1) ? ☰

PV Wizard - Human Limit

Quick PICO **PV Wizard** Advanced Drug Disease Device Article Authors

EMA's MLM searches >

Find best term

Emtree

- anatomical concepts
- biological functions
- biomedical disciplines, science and art
- chemical, physical and mathematical phenomena
- chemicals and drugs
- diseases
- geographic names
- groups by age and sex
- health care concepts
- named groups of persons
- organisms
- procedures, parameters and devices
- society and environment
- types of article or study

Drug name Alternative drug names Adverse drug reactions Special situations **Human limit**

'human'/exp OR human OR m?n OR wom?n OR child OR boy OR girl

Clear query Reset form

Limit to:

Publication years (including):

2018 to 2018

Records added to Embase (including end date):

1-1-2016 to 31-12-2016

Search details

Summary:

```
(([drug]/[subheading] OR [drug]-induced:de,ab,ti) OR ( ([drug]:de OR [variants]:tn,ti,ab) AND ( ([adverse drug reactions]) OR ([special situations]) ) ) ) AND (human limit)
```

Full search strategy

OTFILTRUVYVAEM ISSLEDOVANIYA NA ZHIVOTNYKH

< Previous step Show 138 results >

## 1.6 Автоматизированный пострегистрационный мониторинг безопасности в Embase. Настройка периодических оповещений по электронной почте о появлении новых публикаций в литературе

('everolimus eluting coronary stent'/exp OR 'promus element' OR 'xience xpedition' OR 'xience-v' OR 'everolimus eluting coronary stent')

AND

('adverse device effect'/exp OR 'complication'/exp OR (postoperative NEXT/2 complication\*) OR complicat\* OR 'risk'/exp OR risk\* OR 'side effect'/exp OR (adverse OR side OR undesirable OR unwanted OR lack) NEXT/2 (effect\* OR reaction\* OR event\* OR outcome\*))

### Настройка автоматических оповещений

Embase®

Publication years	▼
Authors	▼
Conference Abstracts	▼
Drug Trade Names	▼
Drug Manufacturers	▼
Device Trade Names	▼
Device Manufacturers	▼

Apply >

OR 'tylenol forte'.in.ab.ti OR 'tylenol nr 1'.in.ab.ti OR 'tyl-  
'zidinol'.in.ab.ti AND ('adverse drug reaction'/exp OR 'ad-  
event' OR outcome\*)):de.ab.ti OR 'side effect'/ink OR 'sic  
'pharmacovigilance'.de.ab.ti OR 'postmarketing surveill-  
OR 'pharmacotox'.de.ab.ti OR 'neurotox'.de.ab.ti OR 'cardi-  
cytotox'.de.ab.ti OR 'carcinogen'.de.ab.ti OR 'cancerogen  
OR 'suicid'.de.ab.ti OR 'mortal'.de.ab.ti OR 'fatal'.de.ab.ti OR  
related disorders'/exp OR 'chemically induced'.de.ab.ti OR  
OR 'withdrawal syndrome'/de OR (drug) NEAR/3 (withdra-  
'drug tolerance'/exp OR 'drug interaction'.ink OR 'drug in-  
NEXT/1 miss\*).ab.ti OR 'ineff'.ti OR 'nonrespon\*.ti OR 'unre-  
NEAR/3 (error OR fault OR mistake OR failure OR 'contan-  
abus\*.de.ab.ti OR 'misus\*.de.ab.ti OR 'off label'.de.ab.ti OR  
'pregnancy disorder'/exp OR 'lactation'/exp OR 'breast fe-  
'prenatal'.de.ab.ti OR 'perinatal'.de.ab.ti OR 'newborn'.de.  
geriatric'.ti OR ((environmental OR occupational) NE  
'prescri\*.de.ab.ti OR 'drug metabolism'/exp OR 'organ dys-  
counterfeit'.de.ab.ti OR 'falsified drug'.de.ab.ti OR ('unav-

33,975 results for search #2

Set email alert

Set R

Results View | Print | Export | Email | Order

Select number of items Selected: 0 (clear)

- Prenatal paracetamol use and asthma in  
Fan G., Wang B., Liu C., Li D.  
[Article in Press] *Allergologia et Immunopathologia* 201  
Embase [Abstract](#) [Index Terms](#) [View](#)
- Effect of tramadol/acetaminophen on m  
Tetsunaga T., Tetsunaga T., Tanaka M., Nishida K., Takei Y., Ozaki T.  
*Pain Research and Management* 2016 2016 Article Number 7458534  
Embase [Abstract](#) [Index Terms](#) [View Full Text](#)

#### Set Email Alert

Email alerts will produce an email with a maximum of 1000 records.

Alert name

Comments (optional)

Email address(es)

Email addresses should be separated by a semi-colon (;)

Email format  HTML  Text  RIS (as an attachment)

Content selection

Frequency  on

Alert sent  Send an alert only when there are results

Articles in Press and in Process  Include

## Новости

Статья Бориса Константиновича Романова ФГБУ «Научный центр экспертизы средств медицинского применения» Минздрава РФ в соавторстве с руководителем направления Elsevier LifeScience Худошиным Андреем Григорьевичем.

### Цитата из тезисов статьи:

«...В работе показаны обязательные требования к системам поиска данных и инструменты оценки их эффективности. Представлены результаты анализа покрытия и приведено сравнение результатов поиска в базах MEDLINE®, Embase® и eLibrary по 35 препаратам. Показано, что поиск в базе данных Embase® обеспечивает максимальное количество источников литературы. **Также показана применимость специализированного конструктора поисковых запросов PV Wizard для разработки стратегий поиска для фармаконадзора, обеспечивающих его полноту и чувствительность...**»

«...Согласно правилам надлежащей практики фармаконадзора ЕАЭС и ЕС, **база Embase® должна быть рекомендована для мониторинга литературы в рамках фармаконадзора. Добавление в базу Embase® конструктора запросов PV Wizard в качестве нового поискового инструмента значительно упростило и ускорило разработку эффективных стратегий поиска, обеспечивающих соответствие установленным нормативным требованиям.**»

<https://doi.org/10.30895/2312-7821-2019-7-1-31-43>

## Мониторинг литературы для фармаконадзора

### БАЛАНС ПОЛНОТЫ И ТОЧНОСТИ В РЕЗУЛЬТАТАХ ПОИСКА MEDLINE®, EMBASE® И ELIBRARY

- Для проверки показателя полноты стратегии поиска отраслевые специалисты в качестве стандарта применяют массивы данных «золотого стандарта» (GOLD dataset), которые включают все релевантные статьи, извлеченные из имеющихся у ДРУ баз данных по безопасности за определенный промежуток времени.
- Если БД позволяет извлечь все имеющиеся в массиве данные — значит полнота поиска составляет 100 %

- Скрининг медицинской литературы

МНН	Строка поиска			Результаты поиска		
	MEDLINE	Embase	eLibrary	MEDLINE	Embase	eLibrary
Нимесулид	nimesulide [Supplementary Concept] OR "nimesulide" [All Fields]	'nimesulide'	nimesulide OR Нимесулид	1656	4634	4194
Ксилометазоллин	xylometazoline [Supplementary Concept] OR "xylometazoline" [All Fields]	'xylometazoline'	xylometazoline OR Ксилометазоллин	289	1311	781
Иматиниб	"imatinib mesylate" [MeSH Terms] OR ("imatinib" [All Fields] AND "mesylate" [All Fields]) OR "imatinib mesylate" [All Fields] OR "imatinib" [All Fields]	imatinib'	imatinib OR Иматиниб	14 164	39 756	13 638
Аспарагиназа	asparaginase [MeSH Terms] OR "asparaginase" [All Fields]	'asparaginase'	asparaginase OR Аспарагиназа	5457	15 423	3738
Октреотид	octreotide [MeSH Terms] OR "octreotide" [All Fields]	octreotide'	octreotide OR Октреотид	9921	22 778	7390
Флударабин	fludarabine [Supplementary Concept] OR "fludarabine" [All Fields]	'fludarabine'	fludarabine OR Флударабин	5493	25 955	5649
Интерферон бета-1а	"interferon beta-1a" [MeSH Terms] OR ("interferon" [All Fields] AND "beta-1a" [All Fields]) OR "interferon beta-1a" [All Fields] OR ("interferon" [All Fields] AND "beta" [All Fields] AND "1a" [All Fields]) OR "interferon beta 1a" [All Fields]	'beta1a interferon'	beta1a interferon OR Интерферон бета-1а	2201	7179	74
Темозоломид	temozolomide [Supplementary Concept] OR "temozolomide" [All Fields]	'temozolomide'	temozolomide OR Темозоломид	6501	22 076	9583
Аминосалициловая кислота	aminosalicylic acid [MeSH Terms] OR ("aminosalicylic" [All Fields] AND "acid" [All Fields]) OR "aminosalicylic acid" [All Fields]	'aminosalicylic acid'	aminosalicylic acid OR Аминосалициловая кислота	6346	15 318	3831
Теризидон	terizidone [Supplementary Concept] OR "terizidone" [All Fields]	'terizidone'	terizidone OR Теризидон	50	420	137
Оксалиплатин	oxaliplatin [Supplementary Concept] OR "oxaliplatin" [All Fields]	oxaliplatin	oxaliplatin OR Оксалиплатин	10 005	34 945	16 187
Золедроновая кислота	zoledronic acid [Supplementary Concept] OR "zoledronic acid" [All Fields]	zoledronic acid'	zoledronic acid OR Золедроновая кислота	4300	14 952	5312

Продолжение таблицы 1

МНН	Строка поиска			Результаты поиска		
	MEDLINE	Embase	eLibrary	MEDLINE	Embase	eLibrary
Паклитаксел	paclitaxel [MeSH Terms] OR "paclitaxel" [All Fields]	'paclitaxel'	paclitaxel OR Паклитаксел	33 613	98 393	52 753
Кетамин	ketamine [MeSH Terms] OR "ketamine" [All Fields]	'ketamine'	ketamine OR Кетамин	18 108	38 878	22 537
Бикалутамид	bicalutamide [Supplementary Concept] OR "bicalutamide" [All Fields]	Bicalutamide	Bicalutamide OR Бикалутамид	1606	5799	1873
Изониазид + Этамбутол	("isoniazid" [MeSH Terms] OR "isoniazid" [All Fields]) AND ("drug combinations" [MeSH Terms] OR "drug" [All Fields] AND "combinations" [All Fields]) OR "drug combinations" [All Fields] OR ("drug" [All Fields] AND "combination" [All Fields]) OR "drug combination" [All Fields] AND ("ethambutol" [MeSH Terms] OR "ethambutol" [All Fields])	'isoniazid'/'drug combination'/'ethambutol' OR Изониазид Этамбутол	ethambutol isoniazid OR Изониазид Этамбутол	1362	4203	3019
Фентанил	fentanyl [MeSH Terms] OR "fentanyl" [All Fields]	fentanyl'	fentanyl OR Фентанил	23 137	63 058	14 073
Апротинин	aprotinin [MeSH Terms] OR "aprotinin" [All Fields]	'aprotinin'	aprotinin OR Апротинин	8136	14 452	12 811
Бусерелин	buserelin [MeSH Terms] OR "buserelin" [All Fields]	buserelin'	buserelin OR Бусерелин	2409	5182	1858
Бикалутамид	bicalutamide [Supplementary Concept] OR "bicalutamide" [All Fields]	bicalutamide'	bicalutamide OR Бикалутамид	1606	5799	1873
Филграстим	filgrastim [MeSH Terms] OR "filgrastim" [All Fields]	filgrastim'	filgrastim OR Филграстим	2582	5399	3089
Азитромицин	azithromycin [MeSH Terms] OR "azithromycin" [All Fields]	azithromycin'	azithromycin OR Азитромицин	8097	31 960	10 158
Лефлуномид	leflunomide [Supplementary Concept] OR "leflunomide" [All Fields]	leflunomide'	leflunomide OR Лефлуномид	2243	10 824	3065
Ибупрофен	ibuprofen [MeSH Terms] OR "ibuprofen" [All Fields]	ibuprofen'	ibuprofen OR Ибупрофен	13 630	48 120	19 907
Адалимумаб	"adalimumab" [MeSH Terms] OR "adalimumab" [All Fields]	adalimumab'	adalimumab OR Адалимумаб	7008	28 549	6150
Инфликсимаб	"infliximab" [MeSH Terms] OR "infliximab" [All Fields]	'infliximab'	infliximab OR Инфликсимаб	13 208	45 326	12 168

- Представлены результаты анализа покрытия и приведено сравнение результатов поиска в базах MEDLINE®, Embase® и eLibrary по 35 препаратам

## Примеры

# При какой концентрации протеина в моче используют тест полоски

Embase®

Search

Entree

Journals

**Results**

My tools

Register

Login

🔔 (1)

?

## Results

 Select Language | ▼

'proteinuria'

Search &gt;

Mapping ▼

Date ▼

Sources ▼

Fields ▼

Quick limits ▼

EBM ▼

Pub. types ▼

Languages ▼

Gender ▼

Age ▼

Animal ▼

Search tips ▼

### Results Filters

+ Expand — Collapse all

Apply &gt;

Sources ▼

Drugs ▼

Diseases ▼

#### Devices

 urine test strip

Details ▶ 201

 test strip

Details ▶ 164

 stent

114

 elisa kit

Details ▶ 101

 fiber

95

 implantable  
cardioverter  
defibrillator

90

 filter

89

+ More

&gt; Export

 History

Save | Delete | Print view | Export | Email

Combine &gt;

using  And  Or

^ Collapse

 #1

'proteinuria'

89,362

89,362 results for search #1

🔔 Set email alert

📡 Set RSS feed

📄 Search details

new 📊 Index miner

 Results

View | Print | Export | Email | Order | Add to Clipboard

1 — 25

&gt;

Selected: 0 (clear)

Show all abstracts

Sort by:  Relevance Publication Year Entry Date
 1

Bilateral corneal perforation and iris prolapse as a complication non-peripheral ulcerative keratitis in a patient with fulminant granulomatosis with polyangiitis: a case report

Vargas-Villanueva A., Carvajal-Saiz N., Muñoz-Ortiz J., de-la-Torre A.

*Journal of Ophthalmic Inflammation and Infection* 2020 10:1 Article Number 2 Cited by: 0

Embase [No abstract available]  Index Terms  View Full Text

new  Similar records >

 2

Do the mefv gene mutations increase in patients with autosomal dominant polycystic kidney disease? Preliminary analysis

Dogan İ., Altunoğlu A., Ozturk C., Kose K., Yuce G., Ersoy O., Erten S.

[In Process] *Annals of Clinical and Analytical Medicine* 2020 11:4 (311-313)

Embase  Abstract  Index Terms  View Full Text

new  Similar records >

 3

Renalase rs10887800 gene polymorphism and its serum level in preeclampsia

El Niadany S.S., El Gayed A.M.A., El Gayed E.M.A.

# Все статьи в которых используют тест полоски в случае протеонурии

## Results

Select Language | ▼

#1 AND 'test strip'/dv

Search >    Mapping ▼    Date ▼    Sources ▼    Fields ▼    Quick limits ▼    EBM ▼    Pub. types ▼    Languages ▼    Gender ▼    Age ▼    Animal ▼

Search tips ▼

### Results Filters

+ Expand    - Collapse all

Apply >

Sources ▼

Drugs ▼

Diseases ▼

Devices ▲

test strip    Details ▶    164

analyzer    5

computer    2

diagnostic kit    2

analytical equipment    1

aneurysm clip    1

**History**    Save | Delete | Print view | Export | Email    Combine >    using  And     Or    ^ Collapse

#2    #1 AND 'test strip'/dv    164

#1    'proteinuria'    89,362

164 results for search #2    Set email alert    Set RSS feed    Search details    <sup>new</sup> Index miner

**Results**    View | Print | Export | Email | Order | Add to Clipboard    1 — 25 >

Select number of items ▼    Selected: 0 (clear)    Show all abstracts |    Sort by:  Relevance     Publication Year     Entry Date

1    **MONITORING RENAL COMPLEMENT ACTIVITY IN PATIENTS WITH C3 GLOMERULOPATHY**  
 May K., Zhang Y., Roberts S., Nestor C., Smith R.  
*Molecular Immunology* 2019 114 (477-)  
 Embase    ▼ Abstract    ▼ Index Terms    > View Full Text    <sup>new</sup> Similar records >

2    **Proteinuria** and risk of lower-extremity amputation in patients with peripheral artery disease  
 Shin J.-I., Grams M.E., Coresh J., Chang A.R., Matsushita K.  
*Diabetes Care* 2019 42:9 (E146-E147) Cited by: 0

# Антифосфолипидный синдром

Embase®

Search

Emtree

Journals

Results

My tools

Register

Login

🔔 (1)

?

## Quick Search

 Select Language | ▼

- Quick
- PICO
- PV Wizard
- Medical device
- New Advanced
- Drug
- Disease
- Device
- Article
- Authors

[Search tips](#)

	Quick search ▼	<input style="width: 95%;" type="text" value="'antiphospholipid syndrome'"/>	✕
AND ▼	Journal name ▼	<input style="width: 90%;" type="text" value="e.g. american heart"/>	🔍 🗑️
AND ▼	Author name ▼	<input style="width: 90%;" type="text" value="e.g. watson j"/>	🔍 🗑️
AND ▼	Author's first name ▼	<input style="width: 90%;" type="text" value="e.g. Mary Jane"/>	🔍 🗑️
<span style="font-size: 1.2em;">+</span> Add search field <span style="font-size: 1.2em;">↺</span> Reset form			

Show 17,479 results >

### Limit to:

Publication years (including):

-

Records added to Embase (including end date):

-  dttt

### Evidence Based Medicine

Cochrane Review     Controlled Clinical Trial

# Какие препараты назначают чаще всего пациентам с антифосфолипидным синдромом

Embase®

Search Emtree Journals **Results** My tools Register Login 🔔(1) ?

Search > Mapping ▾ Date ▾ Sources ▾ Fields ▾ Quick limits ▾ EBM ▾ Pub. types ▾ Languages ▾ Gender ▾ Age ▾ Animal ▾ Search tips ▾

**Results Filters**

+ Expand — Collapse all Apply >

Sources ▾

Drugs ▴

- phospholipid antibody **Details ▶** 6105
- cardiolipin antibody **Details ▶** 3918
- lupus anticoagulant **Details ▶** 3277
- acetylsalicylic acid **Details ▶** 2896
- heparin **Details ▶** 2451
- warfarin **Details ▶** 2378
- immunoglobulin g **Details ▶** 2310
- anticoagulant agent **Details ▶** 2158
- beta2 glycoprotein 1 **Details ▶** 1028

+ More > Export

Diseases ▾

Devices ▾

Floating Subheadings ▾

Age ▾

Gender ▾

Study types ▾

**History** Save | Delete | Print view | Export | Email Combine > using  And  Or ^ Collapse

#1 'antiphospholipid syndrome'/exp OR 'antiphospholipid syndrome' 17,479

17,479 results for search #1 🔔 Set email alert 📡 Set RSS feed 📄 Search details new 📊 Index miner

**Results** View | Print | Export | Email | Order | Add to Clipboard 1 — 25 ▶

Select number of items ▾ Selected: 0 (clear) Show all abstracts | Sort by:  Relevance  Publication Year  Entry Date

1 Massive obstetric hemorrhage during cesarean section in a patient after conception by frozen-thawed embryo transfer: a case report  
Ito M., Oshita K., Tanaka K., Hara M., Hiraki T.  
*JA Clinical Reports* 2020 6:1 Article Number 2  
Embase Abstract Index Terms View Full Text new 📄 Similar records >

2 Visualization and analysis of the interaction network of proteins associated with blood-cell targeting autoimmune diseases  
Amanatidou A.I., Nastou K.C., Tsitsilonis O.E., Iconomidou V.A.  
*Biochimica et Biophysica Acta - Molecular Basis of Disease* 2020 1866:5 Article Number 165714 Cited by: 0  
Embase MEDLINE Abstract Index Terms View Full Text new 📄 Similar records >

3 Subarachnoid Hemorrhage After Ischemic Stroke Associated with Systemic Lupus Erythematosus and Antiphospholipid Syndrome  
Tsukamoto E., Tanei T., Senda J., Kato T., Naito T., Ishii K., Okada K., Hasegawa T.  
*World Neurosurgery* 2020 136 (248-252) Cited by: 0  
Embase MEDLINE Abstract Index Terms View Full Text new 📄 Similar records >

4 Determinants of elevated factor VIII in patients screened for thrombophilia  
Gajek A., Natorska I., Wypasek E., Stanisz A., Malinowski K.P., Undas A.

# Какие побочные эффекты возникают у пациентов с антифосфолипидным синдромом при приеме варфарина

The screenshot displays the Embase search interface. On the left, a sidebar contains various filters such as 'Diseases', 'Devices', 'Age', 'Gender', 'Study types', 'Publication types', 'Journal titles', 'Publication years', 'Authors', 'Conference Abstracts', and 'Drug Trade Names'. The main search results area shows a list of items, with the top result being 'transfer: a case report' by Ito M., Oshita K., Tanaka K., Hara M., and Hiraki T. Two pop-up windows are overlaid on the right side of the page. The first window, titled 'Key subheadings', lists categories like 'adverse drug reaction' (248), 'drug combination' (204), 'drug comparison' (133), 'drug interaction' (28), 'drug therapy' (1636), 'special situation for pharmacovigilance' (9), and 'unexpected outcome of drug treatment' (1). The second window, titled 'Adverse drug reaction', features a search bar and a list of specific reactions including 'bleeding' (67), 'skin necrosis' (21), 'brain hemorrhage' (13), 'thrombosis' (10), 'gastrointestinal hemorrhage' (9), 'embryopathy' (5), 'gangrene' (5), 'alopecia' (3), 'antiphospholipid syndrome' (3), 'calcinosis' (3), 'drug fatality' (3), 'hematoma' (3), 'hematuria' (3), 'hypoplasia' (3), 'recurrent disease' (3), 'thromboembolism' (3), 'unspecified side effect' (3), 'venous limb gangrene' (3), 'adrenal hemorrhage' (2), and 'anemia' (2). The background search results are partially obscured by these windows.

# В комбинации с какими препаратами используют Варфарин у пациентов с антифосфолипидным синдромом

The screenshot shows the Embase search interface. On the left is a sidebar with filters for various categories like Diseases, Devices, and Age. The main area displays search results for 'transfer: a case report' by Ito M., Oshita K., Tanaka K., Hara M., Hiraki T. Two pop-up filters are overlaid on the results:

- Key subheadings:**
  - adverse drug reaction: 248
  - drug combination: 204
  - drug comparison: 133
  - drug interaction: 28
  - drug therapy: 1636
  - special situation for pharmacovigilance: 9
  - unexpected outcome of drug treatment: 1
- Drug combination:**
  - all: 48
  - acetylsalicylic acid: 12
  - heparin: 5
  - clopidogrel: 5
  - low molecular weight heparin: 4
  - enoxaparin: 4
  - hydroxychloroquine: 4
  - prednisone: 3
  - antithrombotic agent: 3
  - prednisolone: 2
  - anticoagulant agent: 2
  - azathioprine: 2
  - cyclophosphamide: 2
  - folic acid: 2
  - hydroxymethylglutaryl coenzyme A reductase inhibitor: 1
  - acenocoumarol: 1
  - alpha adrenergic receptor blocking agent: 1
  - beta adrenergic receptor blocking agent: 1
  - coumarin: 1
  - dalteparin: 1
  - diclofenac: 1
  - digitalis: 1
  - dipeptidyl carboxypeptidase inhibitor: 1

The background search results include:

- Antiphospholipid Syndrome** by Tsukamoto E., Tanei T., Senda J., *World Neurosurgery* 2020 136 (24) Embase MEDLINE [Abstract]
- Determinants of elevated** by Gajek A., Natorska J., Wypasek E., *Thrombosis Research* 2020 188 (2) Embase MEDLINE [No abstract]
- Adherence to infectious c** mediated hematologic di by Malpica-Castillo L.E., Palmer S., Z *American Journal of Hematology* 2 Embase MEDLINE [No abstract]
- Hepatic Complications in** by Chandrasekaran S., Simon R., *Clinical Obstetrics and Gynecology* Embase MEDLINE [Abstract]

# Педиатрия. Используют ли гепарин в случае инсульта у детей

Embase®

Search

## Results

#19 AND [child]/lim

Search > Mapping ▾ Date ▾ Sources ▾ Fields ▾ Quick limits ▾ EBM ▾ Pub. types ▾ Languages ▾ Gender ▾ Age ▾ Animal ▾

### Results Filters

+ Expand — Collapse all

Apply >

Sources ▾

Drugs ▾

- acetylsalicylic acid Details ▶ 549
- endogenous compound Details ▶ 271
- heparin Details ▶ 269
- antibiotic agent Details ▶ 230
- warfarin Details ▶ 211
- immunoglobulin Details ▶ 205
- hemoglobin Details ▶ 198
- steroid Details ▶ 191

+ More > Export

Diseases ▾

Devices ▾

Floating Subheadings ▾

### History

9,420 results for search #20 Set email alert Set RSS feed Search details new Index miner

Results View | Print | Export | Email | Order | Add to Clipboard

Select number of items ▾ Selected: 0 (clear)

1 Interdisciplinary, intensive, activity-based treatment for intrauterine spinal cord

Key subheadings

- adverse drug reaction 12
- drug combination 11
- drug comparison 3
- drug interaction 0
- drug therapy 142
- special situation for pharmacovigilance 0
- unexpected outcome of drug treatment 0

Drug therapy

type any drug therapy (autocomplete) x

- all
- brain infarction 8
- brain ischemia 7
- cerebral sinus thrombosis 6
- occlusive cerebrovascular disease 6
- thrombosis 5
- cerebrovascular accident 4
- deep vein thrombosis 4
- heart infarction 4
- artery dissection 3
- cerebral sinovenous thrombosis 2

4 Hemorrhagic complication

Blood Cells, Molecules, and Diseases

Embase MEDLINE ▾ Abstra

Sobstyl M., Aleksandrowicz M., Z  
Journal of the Neurological Scienc

# В сочетании с какими препаратами используют гепарин в случае инсульта у детей

Embase®

Search Emtree

## Results Filters

+ Expand - Collapse all **Apply >**

Sources ∨

Drugs ∧

- acetylsalicylic acid Details ▶ 549
- endogenous compound 271
- heparin** Details ▶ **269**
- antibiotic agent Details ▶ 230
- warfarin Details ▶ 211
- immunoglobulin Details ▶ 205
- hemoglobin 198
- steroid Details ▶ 191

+ More > Export

Diseases ∨

Devices ∨

## History

9,420 results for search #20 Set email alert Set RSS feed Search details new Index miner

**Results** [View](#) | [Print](#) | [Export](#) | [Email](#) | [Order](#) | [Add to Clipboard](#)

Select number of items ∨ Selected: 0 [\(clear\)](#)

**1** Interdisciplinary, intensive, activity-based treatment for intrauterine spinal cord infarct: A

Key subheadings

<input type="checkbox"/> adverse drug reaction	12
<input checked="" type="checkbox"/> <b>drug combination</b>	<b>11</b>
<input type="checkbox"/> drug comparison	3
<input type="checkbox"/> drug interaction	0
<input type="checkbox"/> drug therapy	142
<input type="checkbox"/> special situation for pharmacovigilance	0
<input type="checkbox"/> unexpected outcome of drug treatment	0

Drug combination

<input type="checkbox"/> all	
<input type="checkbox"/> acetylsalicylic acid	2
<input type="checkbox"/> dipyridamole	2
<input type="checkbox"/> warfarin	2
<input type="checkbox"/> abciximab	1
<input type="checkbox"/> clopidogrel	1
<input type="checkbox"/> lysine acetylsalicylate	1
<input type="checkbox"/> prednisolone	1

Blood Cells, Molecules, and Diseases

Embase MEDLINE ∨ Abstracts

Monograph, compilation

beta-thalasse

thrombotic e

computed to

# Медицинские процедуры при раке молочной железы

## 'medical procedures'/exp #4 AND 'breast cancer'/de

Embase®

 Search Emtree Journals **Results** My tools Alexey Moiseev Logout (1) 

## Results

Выбрать язык | ▼

#4 AND 'breast cancer'/de

Search &gt; Mapping ▾ Date ▾ Sources ▾ Fields ▾ Quick limits ▾ EBM ▾ Pub. types ▾ Languages ▾ Gender ▾ Age ▾ Animal ▾

Search tips ▾

## Results Filters

 + Expand — Collapse all Apply >

Sources ▾

Drugs ▾

Diseases

 breast cancer Details ▶ 305911 neoplasm Details ▶ 42232 metastasis Details ▶ 28852 prostate cancer Details ▶ 21762 lung cancer Details ▶ 21106 ovary cancer Details ▶ 18618 colorectal cancer Details ▶ 16992 lymph node metastasis Details ▶ 13144 breast carcinoma Details ▶ 13107

+ More &gt; Export

Devices ▾

Floating Subheadings ▾

Age ▾

## History

 305,911 results for search #5 Set email alert Set RSS feed Search details <sup>new</sup> Index miner

 **Results** View | Print | Export | Email | Order | Add to Clipboard

1 — 25

 Select number of items ▾ Selected: 0 [clear](#)

 Show all abstracts | Sort by:  Relevance  Publication Year  Entry Date

 **1** Successful anesthetic management for total mastectomy in a pregnant woman using general anesthesia combined with continuous erector spinae plane block: a case report

Sawada A., Sotome S., Kusakai M., Yamakage M.

JA Clinical Reports 2019 5:1 Article Number 23

 Embase  Abstract  Index Terms > View Full Text
<sup>new</sup> Similar records >
 **2** Multiple ABCB1 transcriptional fusions in drug resistant high-grade serous ovarian and breast cancer

Christie E.L., Pattnaik S., Beach J., Copeland A., Rashoo N., Fereday S., Hendley J., Alsop K., Brady S.L., Lamb G., Pandey A., deFazio A., Thorne H., Bild A., Bowtell D.D.L.

Nature Communications 2019 10:1 Article Number 1295 Cited by: 0

 Embase MEDLINE  Abstract  Index Terms > View Full Text
<sup>new</sup> Similar records >
 **3** Brain metastases

Achrol A.S., Rennert R.C., Anders C., Soffiotti R., Ahluwalia M.S., Nayak L., Peters S., Arvold N.D., Harsh G.R., Steeg P.S., Chang S.D.

Nature Reviews Disease Primers 2019 5:1 Article Number 5 Cited by: 0

 Embase MEDLINE  Abstract  Index Terms > View Full Text
<sup>new</sup> Similar records >
 **4** UPLC-ESI-PDA-MS<sup>n</sup> profiling of phenolics involved in biological activities of the medicinal plant Halocnemum Strobilaceum (Pall.)

Handoussa H., Abdallah W., Abdelmohsen M.

# Off label применение ритуксимаба с помощью тройного индексирования

Embase®

Search

4,099 results for search #2 [Set email alert](#) [Set RSS feed](#) [Search details](#) [Index miner](#)

- Drugs
  - monoclonal antibody **Details ▶** 2771
  - rituximab **Details ▶** 1569
  - bevacizumab **Details ▶** 566
  - antibody **Details ▶** 527
  - cetuximab **Details ▶** 443
  - cyclophosphamide **Details ▶** 433
  - trastuzumab **Details ▶** 410
  - vasculotropin **Details ▶** 350
  - unclassified drug 340
- Click on 'Apply' to apply your selection
- [+ More](#) [Export](#)
- Diseases
- Devices
- Floating Subheadings
- Age
- Gender
- Study types
- Publication types
- Journal titles
- Publication years

**Key subheadings**

- adverse drug reaction 37
- drug combination 80
- drug comparison 21
- drug interaction 2
- drug therapy 238
- special situation for pharmacovigilance 0
- unexpected outcome of drug treatment 0

**Drug therapy**

type any drug therapy (autocomplete)

- all
- nonhodgkin lymphoma 33
- chronic lymphatic leukemia 20
- large cell lymphoma 16
- lymphoma 13
- follicular lymphoma 10
- B cell lymphoma 9
- malignant neoplasm 8
- rheumatoid arthritis 5
- hematologic malignancy 4
- mantle cell lymphoma 4
- Hodgkin disease 3
- breast cancer 2
- neoplasm 2
- opsoclonus myoclonus syndrome 2
- acute lymphoblastic leukemia 1
- autoimmune hemolytic anemia 1
- Burkitt lymphoma 1
- cerebellum degeneration 1
- childhood disease 1
- colorectal cancer 1
- diffuse large B cell lymphoma 1

3 **Toward identifying optim**  
 Cooks T., Theodorou S.D., Papanicolaou G.A., et al. [In Process] *Histology and histopathology* 2019 53:1-10  
 MEDLINE  Abstract  Full Text

4 **Triple-drug chemotherap**  
 Matos I., Noguero A., Ros J., et al. [Article in Press] *Expert opinion on drug safety* 2019 18:1-10  
 MEDLINE  Abstract  Full Text

5 **Human endotrophin as a**  
 Bu D., Crewe C., Kusminski C.M., et al. [In Process] *JCI insight* 2019 5:1-10  
 MEDLINE  Abstract  Full Text

- Off label применение ритуксимаба

# Как изменяется количество публикаций на эту тему.

Embase®

methotrexate	Details	156
<a href="#">+ More</a>	<a href="#">&gt; Export</a>	
Diseases	▼	
Devices	▼	
Floating Subheadings	▼	
Age	▼	
Gender	▼	
Study types	▼	
Publication types	▼	
Journal titles	▼	
<u>Publication years</u>	▲	
<input type="checkbox"/> 2019	12	▲
<input type="checkbox"/> 2018	73	
<input type="checkbox"/> 2017	79	
<input type="checkbox"/> 2016	80	
<input type="checkbox"/> 2015	177	
<input type="checkbox"/> 2014	181	
<input type="checkbox"/> 2013	174	
<input type="checkbox"/> 2012	193	
<input type="checkbox"/> 2011	105	▼
<a href="#">&gt; Export</a>		
Authors	▼	
Conference Abstracts	▼	
Drug Trade Names	▼	
Drug Manufacturers	▼	

<input type="checkbox"/> 2	Toward identifying opt Jalali R. <i>Neuro-Oncology Practice</i> 2019 Embase [No abstract availa
<input type="checkbox"/> 3	Predictions and Statist Lindsley C.W. <i>ACS Chemical Neuroscience</i> 20 Embase MEDLINE [No abs
<input type="checkbox"/> 4	INFLAMMATION AND I Tseng S., Khoury M., Singh N. <i>Journal of the American Colleg</i> Embase Abstract
<input type="checkbox"/> 5	Switched memory B-ce Shields A., Anderson R., McCa <i>British Journal of Haematology</i> Embase Abstract
<input type="checkbox"/> 6	Investigating the Poter Durand-Panteix S., Cogne M., <i>Journal of Medical Imaging and</i> Embase Abstract
<input type="checkbox"/> 7	What does the pipeline Busse A., Lüftner D. <i>Breast Care</i> 2019 14:1 (10-16) Embase Abstract
<input type="checkbox"/> 8	Rituximab Use and Imi Barmettler S., Ong M., Farme <i>Journal of Allergy and Clinical I</i> Embase Abstract
<input type="checkbox"/> 9	Current and future on Runyan A., Banks J., Bruni D.S

число публикаций по терапии rituximab при follicular lymphoma



'oncology'/exp AND 'rituximab'/de AND ('rituximab'/de OR 'rituximab'/'drug therapy'/'follicular lymphoma')

# Когорты пациентов

Floating Subheadings ∨

---

Age ∧

<input type="checkbox"/> Embryo	157828
<input type="checkbox"/> Fetus	153079
<input type="checkbox"/> Newborn	411611
<input type="checkbox"/> Infant	475040
<input type="checkbox"/> Child (1-12)	1563092
<input type="checkbox"/> Preschool child (1-6)	408232
<input type="checkbox"/> School child (7-12)	293612
<input type="checkbox"/> Adolescent	1145367
<input type="checkbox"/> Young adult	222537

[Export](#)

---


Gender ∧



Male: (6748375)



Female: (6914808)





# Медицинские процедуры (medical procedures)



- ⊕ Emtree
  - ⊕ procedures, parameters and devices
    - ⊕ procedures
      - ⊖ **medical procedures**  [24,173,227 Records](#)
        - ⊕ administration of drugs, food and chemicals
        - ⊕ anesthesiological procedure
        - ⊕ aspiration, puncture and suction
        - bandaging technique
        - ⊕ cannulation
        - ⊕ cardiovascular procedure
        - ⊕ dental procedure
        - ⊕ depletion
        - ⊕ dermatological procedure
        - ⊕ diagnostic procedure
        - ⊕ gastroenterological procedure
        - ⊕ hematological procedure
        - ⊕ intubation
        - invasive procedure
        - ⊕ minimally invasive procedure
        - ⊕ musculoskeletal procedure
        - ⊕ neurological and sensorial procedures
        - ⊕ non invasive procedure
        - ⊕ obstetric procedure

- ⊕ oncological procedure
- ⊕ prosthetic procedure
- ⊕ psychological and psychiatric procedures
- repeat procedure
- ⊕ reproductive procedure
- sham procedure
- ⊕ stereotactic procedure
- ⊕ surgery
- ⊕ therapy
- unnecessary procedure
- ⊕ urological procedure

## СТОМАТОЛОГИЯ



# Акушерство и гинекология



# Педиатрия




Age		^
<input type="checkbox"/> Embryo	635	▲
<input type="checkbox"/> Fetus	984	
<input type="checkbox"/> Newborn	3656	
<input type="checkbox"/> Infant	3351	
<input type="checkbox"/> Child (1-12)	9420	
<input type="checkbox"/> Preschool child (1-6)	2295	
<input type="checkbox"/> School child (7-12)	2246	
<input type="checkbox"/> Adolescent	8407	
<input type="checkbox"/> Young adult	2624	▼

> Export


# Аутоиммунные заболевания

autoimmune disease	X
⊙ autoimmune diseases of the nervous system use: neurologic disease	3,826,419
⊙ autoimmune disease	642,372
⊙ autoimmune diseases use: autoimmune disease	642,372
⊙ autoimmune disease immunofluorescence assay	52
⊙ autoimmune disease immunofluorescence assay kit	51
⊙ autoimmune disease ifa kit use: autoimmune disease immunofluorescence assay kit	51
⊙ autoimmune disease test kit	33
⊙ autoimmune disease ELISA kit	16

## Онкология.



## Резистентность к антибиотикам 160,690 записей





**Информационные решения в области искусственного интеллекта позволяют исключить требуется повторные манипуляции с информацией (поиск информации, сортировка, переписывание, сбор) литературный обзор.**



**«Единственное что не умеет искусственный интеллект, это думать критически, пользоваться своим воображением, принимать решения, и осознанный делать выбор»**

**Митио Каку**

**ученый, футуролог, популяризатор науки**

# Спасибо за внимание!



## Вопросы?

Алексей Моисеев,  
МВА, директор по развитию и обслуживанию клиентов Elsevier LifeScience  
в России, Турции и СНГ

Email [a.moiseev@elsevier.com](mailto:a.moiseev@elsevier.com)  
Моб. [+79251131255](tel:+79251131255)